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ABSTRACT OF THE DISSERTATION
Methods to Record Transcription Factor Binding and Enhancer Activity throughout Cellular
Differentiation.
by
Zongtai Qi
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Genetics and Genomics
Washington University in St. Louis, 2018
Professor Andrew Yoo, Chair

The ability to create distinct cell types is fundamental for the development of multicellular
organisms. Since all cells in an organism contain the same genes, cellular diversity is achieved
through the transcriptional network where transcription factors (TFs) interacts with cisregulatory elements, leading to the selective transcription of different sets of genes. To better
understand the functions of TFs and regulatory elements underlying cell fate decisions, we
developed methods that are able to record their activities throughout cellular differentiation. In
Chapter 2, we developed a degradation domain based induction system for “Calling Cards”
method which maps the binding sites of TFs using piggybac transposons. The induction “Calling
Cards” method offers an alternative to chromatin immunoprecipitation (ChIP) methods and
furthermore has the ability to record TF binding at different time periods of the development. In
Chapter 3, we applied the “Calling Card” method to study the role of master regulatory Brd4bound enhancers for sex differences in glioblastoma. We revealed a set of sex-specific regulatory
genes and networks, which are indicative of sex-specific transcriptional programs regulated by
ix

Brd4-bound enhancers. Finally, to record the activity of regulatory elements or enhancers, in
Chapter 4, we developed a CRE recombinase-mediated method for high-throughput functional
identification of active enhancers at different time periods of the development, named as
Developmental Enhancer Sequencing (DevEn-seq). We demonstrated that DevEn-seq is able to
detect enhancers more efficiently than regular reporter methods and trace enhancer activities
throughout cellular differentiation without being disturbed by the gene silencing effect caused by
lentiviral sequences. With an in vitro neural differentiation protocol, we identified two neural
progenitor-specific enhancers near HB9 and Olig2 genes respectively. In summary, this
dissertation contributes to the field of developmental biology by providing useful methods for
recording TF binding events and enhancer activities throughout development.
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Chapter 1
Introduction
1.1 Development of an inducible transposon “Calling Card” method
1.1.1 The transposon “Calling Card” method can record transcription factor binding.
Vertebrate development is transcriptionally regulated, thus considerable effort has been
expended on understanding the gene expression networks that control this process1. However,
mapping these transcriptional networks has proven difficult. Methods like ChIP-Chip or ChIPSeq can analyze transcription factor binding in homogenous populations of cells but are unable
to record transcription factor binding events along different cellular lineages. This make it
impossible to correlate transcription factor binding events in progenitor cells to the final fates of
their progeny, complicating efforts to understand the mechanisms by which cell fates are
determined.
We have developed transposon “Calling Cards”, a method designed to record transcription
factor binding during development2. The central idea behind the Calling Card method is to attach
the transposase of a transposon to a transcription factor (TF), thereby bestowing on the TF the
ability to direct insertion of the transposon into the genome near to where it binds. The
transposon is a “Calling Card” that permanently marks the transcription factor’s visit to a
particular genomic location. By harvesting the transposon Calling Cards along with their
flanking genomic DNA, it is possible to obtain a genome-wide map of transcription factor
binding.

1

1.1.2 An “inducible” Calling Card method is useful in studying TF bindings underlying cell
fate decisions.
In developmental biology, the decision of into what terminal cell fate a progenitor cell
differentiates is a critical step in creating the architecture of multicellular organisms. These
choices are often directed by some key TFs known as master regulators of gene regulation3, 4.
These TFs may display disparate functions at different times during neural development5, 6. To
use transposon “Calling Card” method to understand these key TFs’ bindings underlying cell fate
decisions in development, it is important to control the timing of TF-directed transposition events
to those early in the differentiation process rather than the mature states. To achieve this goal, we
need to create an inducible piggybac (PB) transposon system on which the CC method is built so
that we are able to turn on and off the transposition events for TF recording. An inducible PB
transposon system can be made at two molecular levels: transcriptional and post-translational
levels. Because we want the transposon system to react promptly to an inducer, the molecular
control at post-translational level is more favored.

1.1.3 Degradation domains allow a rapid post-translational induction system.
Molecular tools that regulate protein stability at a post-translational level in live cells
include protein degron systems induced by auxin, light, or destabilizing domains (DDs)7-10. Here,
we focus on the DD-based degron system, which involves genetically fusing the protein of
interest to a small unstable protein domain. This DD fusion protein is recognized by the cellular
protein quality control machinery, which then degrades the entire fusion protein. However, in the
presence of a DD-specific small molecule, the DD assumes a folded state and becomes stable,
allowing the target protein to perform its regular biochemical function11.
2

Two versions of DD induction systems were developed that control target protein levels in
a rapid, reversible and tunable fashion9, 10. The first engineered DD is based on a human FK506rapamycin-binding protein (FKBP) with 107 amino acid residues. Point mutations in FKBP
(F36V and L106P) confer instability to fusion partners, which can be rescued by the cellpermeable high-affinity small molecule, Shield-19. The second DD is engineered from an
Escherichia coli dihydrofolate reductase (DHFR) protein with 159 amino acid residues.
Similarly, a few key mutations confer instability to DHFR, which can be rescued by a highly
permeable small molecule, Trimethoprim (TMP)10. These two induction systems have been
demonstrated to function in a variety of contexts, including mammalian cell cultures, live mice,
viral infections, and in pathogens like Plasmodium and Toxoplasma9, 10 12-15. However, both
FKBP and DHFR DDs display high levels of background in the absence of any molecule
indcuer15. This basal level of expression is sometimes sufficient for the target fusion protein to
perform its regular biochemical function and thereby precludes the observation of any loss-offunction phenotype15. The double architecture for DDs has recently been shown to minimize the
background expression levels15, but a systematic exploration should further expand the uses of
these powerful induction systems.

1.1.4 Degradation domains are utilized to develop an inducible transposon “Calling Card”
method.
We sought to develop a PB transposon induction system for “Calling Card” method that
provides a tightly regulated transposase enzyme that displays a large difference in activity
between the induced and un-induced state, that, when induced, deposits transposons with an
efficiency equal to that of the native protein, that is highly active across a wide variety of cell
3

types, and that is induced with a small molecule that has minimal effects on general cellular
functions. To do so, we tagged PB transposase with two different destabilized domain (DD)
proteins, FK506- and rapamycin binding protein (FKBP)9 and dihydrofolate reductase (DHFR)10,
and compared these to the ERT2 based induction system16 in four different cell lines. To identify
the optimal transposon induction system for “Calling Card” method, we systematically
characterized, in four cell lines, 15 different PB transposase fusion proteins representing three
different induction systems. We found that the FKBP-based system achieved the broadest
dynamic range of induction across four cell lines. Remarkably, in the presence of chemical
inducer, this system had transposition efficiencies that were almost as high (~95%) as the “wildtype” PB transposon. We also investigated the effects of the inducer molecules on differentiation
and found that Shld1 does not affect ESC development. Taken together, the FKBP-based PB
transposon induction system is selected for “Calling Cards” method. This work was described in
chapter 2.

1.2 Application of the “Calling Card” method to study the role of Brd4-bound
enhancers for sex differences in glioblastoma
1.2.1 Sex-dimorphism in glioblastoma is a cell-intrinsic property.
The sexual dimorphism observed in glioblastoma (GBM) is thought to be driven largely by
cell-intrinsic factors. This conclusion is supported by two lines of evidence. First, pediatric brain
cancers display the same sexual dimorphism in incidence as is observed in adult brain cancers. In
these instances, the patients are pre-pubescent, so males and females have similar hormonal
profiles17, 18. Second, the Rubin lab has recapitulated the observed sex-disparity in a cell culture
model of GBM. In this system, male NF1 null astrocytes expressing a dominant negative form
4

of p53 (NF1-/-;DNp53) exhibit increased tumorigenesis and cell proliferation relative to female
NF1-/-;DNp53 astrocytes, independent of hormonal exposure19. In other words, when the male
transgenic astrocytes are implanted into female hosts, the increase in tumor size and growth is
still greater than female transgenic astrocytes implanted into male hosts. These two lines of
evidence support the hypothesis that the sexual dimorphism in GBM occurrence is a cell intrinsic
property.

1.2.2 Epigenetic regulatory mechanism may play a key role in establishing sex differences
in GBM.
Since sex differences in GBM are cell intrinsic, epigenetic regulatory mechanisms may be
a key mediator of these differences20, 21. Evidence of sex specific epigenetic effects in the brain
can be found in the bed nucleus of the stria terminalis (BNST), which is known to have sexdependent differences in structure22. Histone deacetylase (HDAC) inhibitors applied to the
BNST of male mice result in female-like volume and cell number, and suggests that histone
marks play a role in sexually dimorphic cell growth and apoptosis23. Though epigenetic
regulation of cancer states have been studied24, 25, their role in GBM sex-disparity is unknown.

1.2.3 Epigenetic reader Brd4 establishes cell identity and regulates oncogenes.
One mediator of cell identity and disease state is the epigenetic reader BRD4, a protein
from the BET family of chromatin regulators that bind acetylated histones via its
bromodomains26. BRD4 activity is abolished when these domains are blocked by drugs such as
JQ127. BRD4 binding to acetylated histones mediates recruitment of transcriptional activators
and promotes gene expression independent of common transcriptional recruiters such as
5

pTEFb26, making it a key regular in gene transcription28. BRD4 is also known to be one of the
few chromatin regulators that are present during cell division29, which is consistent with its
established role in promoting cellular proliferation. Interestingly, BRD4 has also been shown to
acetylate H3K122, a mark which destabilizes the nucleosome and is correlated with active
transcription of surrounding genes30. This correlates with BRD4’s known role in maintaining cell
proliferation in rapidly differentiating cells31, and may be a key mechanism for maintaining the
proliferative “stem-like” cancer cells.
BRD4 also has been shown to promote tumorigenesis in multiple myeloma (MM) cell line
where BRD4 regulates the expression of specific oncogenes such as c-MYC. JQ1 treatment of
MM cell lines results in a global decrease in BRD4 enhancer binding32, and a subsequent
decrease in gene expression. Global decrease in BRD4 binding results in a decrease in oncogene
expression in human GBM cell lines as well, and demonstrates BRD4’s role as a regulator of
oncogenic potential32.

1.2.4 The “Calling Card” method is used to decipher the Brd4-bound enhancers.
BRD4s regulation of oncogenic potential gives insight into the role of BRD4 in GBM. In
addition, we have experimentally demonstrated that JQ1 has sex-specific effects on
clonogenicity and tumorigenesis, in which males exhibit a decrease in these traits while females
exhibit no effect or an increase in these traits. RVX208, a drug with a higher BRD2 affinity than
a BRD4 affinity, does not exhibit such drastic effects. Therefore, we hypothesized that BRD4 is
a mediator of the increased clonogenicity in males and used transposon “Calling Cards” method
to identify the BRD4-bound enhancers in both male and female GMB cells.

6

Integration of Brd4 Calling Cards, H3K27ac ChIP-seq and RNA-seq data in GBM cells
revealed a set of sex-specific regulatory genes and networks. Male-specific JQ1-sensitive
targetable genes demonstrated functional enrichment for neoplasm metastasis, tumor
angiogenesis, integrin signaling pathway, and DNA-repair-deficiency disorders. Female-specific
JQ1-sensitive targetable genes showed an enrichment in pathways involved in semaphorin
signaling, chromosome aberrations, glioblastoma, regulation of transcription, and glucose
metabolism disorders. These results are indicative of sex-specific transcriptional programs
regulated by Brd4-bound enhancers. This work is described in chapter 3.

1.3 Development of a high-throughput functional identification of enhancers
using a CRE recombinase mediated reporter assay
1.3.1 Enhancer and super enhancer play a fundamental role in cellular differentiation.
Enhancers are a class of noncoding regulatory DNA sequences that can activate
transcription independently of their location, distance or orientation with respect to the promoters
of the genes they control33, 34. Their activity is frequently tissue-specific or cell type-specific35-37.
Hundreds of thousands of candidate enhancers have been annotated in the human genome so far,
compromising at least 12% of the total DNA sequences38, 39. A majority of these sequences
display chromatin accessibility or characteristic patterns of histone modifications in a cell typespecific fashion, supporting their roles in mediating cell type-specific gene expression programs.
Variations at enhancer sites, either single-nucleotide variants or copy-number variants, are
known to be directly associated with a variety of human diseases40, 41. In mice, individual
deletions of enhancers have been shown to considerably alter development42-45. Further, the
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enhancer sequences are enriched in transcription factor-binding motifs, providing clues to the
lineage-specific transcription factors that work at these sequences46.
Among the large number of candidate enhancers predicted in the human and mouse
genomes, a small fraction of them drew special attention. These sequences, referred to as superenhancers, are dense clusters of enhancers and are found in virtually every mammalian cell and
tissue type examined47. They are bound by an extraordinary amount of transcription factors and
cofactors and are typically associated with high levels of transcription activities in specific cell
types. Found particularly enriched at cell identity genes, super-enhancers are regarded as the key
control elements of lineage specification.

1.3.2 Current methods have challenges for high-throughput identification of cell-specific
enhancers in development.
DNase I hypersensitivity assay led to the discovery of numerous mammalian enhancers,
such as the beta-globin locus control region (LCR)48 critical for the developmental control of
beta-globin genes in mammals34, 49. This approach has undergone several iterations from the
laborious Southern blot analysis49 to the high-throughput microarray 50 and the ultrahighthroughput DNA-sequencing analysis that has been now broadly applied to hundreds of cell
types46, 51. The latest iteration of this assay is the use of a genetically engineered TN5 transpose,
instead of DNase I, in a highly streamlined experimental protocol called ATAC-seq (assay for
transposase-accessible chromatin with high-throughput sequencing)52. ATAC-seq is especially
amendable to very small cell numbers and even single cells53, 54. However, DNase I
hypersensitivity is not unique to enhancers. Other cis regulatory elements such as promoters and
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insulators also show this property55. Therefore, just the presence of DNase I hypersensitivity
signal alone is not sufficient to distinguish these different classes of cis regulatory elements.
With the development of ChIP-seq to map transcription factor’s binding sites and
chromatin modification patterns in the genome56, 57, it was possible to show that promoters,
enhancers, and insulators are differentially occupied by transcription factors and are associated
with distinct chromatin modification patterns58, 59. This allowed genome-wide determination of
candidate enhancers. For instance, binding sites of p300, a coactivator protein and histone
acetyltransferase that acts at enhancers, led to annotation of several thousand enhancers in
embryonic brain and limbs in the mouse60. Mapping of DNA occupancy of transcription factors
such as Sox2, Oct4, and Nanog also provided the first enhancer map in the human embryonic
stem cells61, 62.With the increased understanding of the role of histone modification processes in
nucleosome dynamics and chromatin organization, it was natural to examine the chromatin
modification patterns in the genome since different classes of cis regulatory elements may recruit
different chromatin remodeling proteins that generate distinct patterns of histone modifications.
This hypothesis was supported by the observation that enhancers are associated with high levels
of H3K4me1 and low levels of H3K4me3, while the opposite is true for promoters63. The finding
led to the development of chromatin signature-based strategy for mapping enhancers, and
identification of such DNA in both mouse and human genomes64, 65.
Despite these major advances in identifying enhancers, a number of important questions
remain. What are the biological functions of the annotated enhancers? How do they contribute to
cell type-specific gene expression programs? The lack of comprehensive, functionally validated
enhancer data sets for most tissues and cell types has prohibited the systematic exploration of
these questions.
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1.3.3 The CRE-mediated reporter assay allows a high-throughput functional identification
of cell specific enhancers in development.
To overcome the challenges mentioned above, we developed a CRE recombinase-mediated
method for the functional identification of active enhancers at different time periods of the
development, named as Developmental Enhancer Sequencing (DevEn-seq). DNA test fragments
containing putative enhancers are linked to an inducible CRE recombinase and then are
integrated into genome by lentiviruses. If the enhancer is active in a cell, CRE recombinase will
be expressed and activate RFP reporter and permanently generate red cells in itself and its
progeny. ES cell libraries can be differentiated in vitro before sorting and sequencing. We
demonstrated that DevEn-seq is able to detect enhancers more efficiently than regular reporter
methods and record enhancer activities throughout cellular differentiation without being
disturbed by gene silencing effect caused by lentiviral sequences. Coupled with high-throughput
sequencing, DevEn-seq enables a high throughput method for functional identification and
tracking of enhancer activities. This work is described in chapter 4.
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Chapter 2
An optimized, broadly applicable piggyBac
transposon induction system
Published in Nucleic Acids Research. (2017)

2.1 Abstract
The piggyBac (PB) transposon has been used in a number of biological applications. The
insertion of PB transposons into the genome can disrupt genes or regulatory regions, impacting
cellular function, so for many experiments it is important that PB transposition is tightly
controlled. Here, we systematically characterize three methods for the post-translational control
of the PB transposon in four cell lines. We investigated fusions of the PB transposase with ERT2
and two degradation domains (FKBP-DD, DHFR-DD), in multiple orientations, and determined
(i) the fold-induction achieved, (ii) the absolute transposition efficiency of the activated construct
and (iii) the effects of two inducer molecules on cellular transcription and function. We found
that the FKBP-DD confers the PB transposase with a higher transposition activity and better
dynamic range than can be achieved with the other systems. In addition, we found that the
FKBP-DD regulates transposon activity in a reversible and dose-dependent manner. Finally, we
showed that Shld1, the chemical inducer of FKBP-DD, does not interfere with stem cell
differentiation, whereas tamoxifen has significant effects. We believe the FKBP-based PB
transposon induction will be useful for transposon-mediated genome engineering, insertional
mutagenesis and the genome-wide mapping of transcription factor binding.
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2.2 Introduction
Transposons are genetic elements that are able to mobilize throughout a host genome
autonomously. Due to their mobility, DNA transposons and retrotransposons have been widely
used as tools for generating mutation libraries and for delivering non-viral gene constructs into
the genomes of a variety of organisms 66. The use of DNA transposons in mammalian genomes,
however, was initially impeded by a lack of active transposable elements. The synthetic
resurrection of Sleeping Beauty (SB), a Tc1/mariner-like transposable element of the salmanoid
fish genome, initiated the development of transposon technologies for use in mammalian cells 67.
Since then, several other transposon systems have been developed 68-70, including the piggyBac
(PB) system, derived from the cabbage looper moth Trichoplusia ni 71. This system is widely
used because the PB transposon consistently exhibits high transposition efficiencies in different
cell lines and organisms 72, can transpose cargos of up to 100 kb without a significant reduction
in efficiency 73, mobilizes without leaving footprint mutations at the excision site, and is
amenable to molecular engineering 16. In addition, the PB system is highly efficient for germ line
insertional mutagenesis in mice and lacks overproduction inhibition 74. These unique
characteristics make the piggyBac transposon an invaluable tool for a wide range of applications,
including stable gene delivery 75, transgene excision 76, insertional mutagenesis 77, and the
mapping of transcription factor (TF) binding in eukaryotic genomes 2, 78, 79. For many of these
applications, the PB transposon is engineered to act as a gene trap that will disrupt genes when
inserted into the genome 77, so it is useful to be able to tightly control PB transposition so that
insertion only occurs during the proper experimental window, and not, for example, during the
propagation of cell lines or mice. For other applications, such as the mapping of TF binding to
genomic DNA by PB transposition 2, 78, 79, the constitutive activity of the PBase prevents the
12

determination of the precise timing of the binding events, a feature that is particularly useful
when studying developmental processes. Therefore, a method for induction that can tightly
regulate the temporal activity of the PB transposon system is desirable. Furthermore, posttranslational control is appealing because protein activity can be switched on or off considerably
faster than is possible with transcriptional control schemes 9, 10.
Prior to the work presented here, the only existing inducible PB transposon system that
operated post-translationally utilized the mutated ligand-binding domain of the estrogen receptor
(ERT2) 16. The PBase-ERT2 fusion is constitutively expressed but is sequestered outside of the
nucleus by the cytoplasmic heat shock protein 90 (HSP90), which binds the ERT2 domain (Fig
2.1A). In the presence of a small molecule inducer (4-Hydroxy tamoxifen; 4OHT), HSP90
binding is abolished and the PBase-ERT2 fusion rapidly relocates to the nucleus where it directs
transposition. The PBase-ERT2 fusion works well in several contexts [14], but our early
experiences with this system revealed that dynamic range of induction varies widely between
different cell types, possibly due to differences in HSP90 levels, which is not constant across cell
types 80-83. We further found that ERT2-PBase fusions are not highly active when induced
(relative to the unfused transposase, see results). Finally, we found that the chemical inducer
4OHT inhibited the in vitro differentiation of mouse embryonic stem cells, an observation
consistent with similar reports that 4OHT adversely affects neurogenesis 84, myelinogenesis 84,
myometrial differentiation 85, and sexual maturation 86.
In light of these observations, we sought to develop a PB transposon induction system that
provides a tightly regulated transposase enzyme that displays a large difference in activity
between the induced and un-induced state, that, when induced, deposits transposons with an
efficiency equal to that of the native protein, that is highly active across a wide variety of cell
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types, and that is induced with a small molecule that has minimal effects on general cellular
functions. To do so, we characterized and optimized fusions of the PB transposase with two
different destabilized domain (DD) proteins, FK506- and rapamycin binding protein (FKBP) 9
and dihydrofolate reductase (DHFR) 10, and compared these to the ERT2 based induction system
16

in four different cell lines. Destabilized domains are small, inherently unstable proteins that

bind small molecules and have been destabilized by mutation. When fused to PBase, the mutated
domain unfolds and the fusion protein is degraded by the proteosome (Fig 2.1B). However, if
the cognate small molecule ligand is provided, the DD is stabilized and the PBase fusion protein
is rescued from degradation and transposase activity is restored in a rapid, dose-dependent, and
reversible manner. Unlike the ERT2-based system where induction is mediated by a specific
cytoplasmic protein HSP90, DD degradation is mediated by the ubiquitin-proteasome pathway, a
common protein degradation mechanism that is active in all mammalian cells 11, 87.
To identify the optimal configuration for each of the three induction systems, we
investigated 15 different fusions of the PB transposase with FKBP, DHFR or ERT2, and
measured the fold-induction of activity between the uninduced and induced states, the maximum
transposition rate of the activated constructs as compared to the unfused piggyBac transposase,
and the effects of two of the inducer molecules on cellular transcription and differentiation.
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Figure 2.1 Schematic illustration of the ERT2 and DD based PB transposon induction
systems. (A) For the ERT2-based PB transposon induction system, the PBase-ERT2 fusion is
constitutively expressed but sequestered outside of the nucleus by HSP90, which binds the ERT2
domain. In the presence of ER antagonist 4-OHT, HSP90 dissociates and the PBase-ERT2 fusion
rapidly relocates to the nucleus where it directs transposition. (B) For the DD-based PB
transposon induction system, a DD (either FKBP or DHFR) was fused to the PBase. The DD
confers the instability to the fused protein such that the PBase fusion protein was constitutively
degraded. However, binding of a small molecule ligand (Shld1 for FKBP; TMP for DHFR) to
the DD prevents PBase from degradation and stabilizes it.

2.3 Results
2.3.1 Overview
We evaluated and optimized three induction systems for their abilities to provide tight
post-translation control over the PB transposon. We used one degradation domain (DD) derived
from human FKBP12 (FKBP) 9 and another from Escherichia coli dihydrofolate reductase
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(DHFR) 10 and compared these against the ERT2-based system in four different cell lines: human
embryonic kidney cells (HEK293 and HEK293T), human colorectal cancer cells (HCT116), and
RW4 mouse embryonic stem cells (ESCs). To obtain the most efficient induction possible, a
number of different fusions constructs were investigated for each system (Fig 2.2). We fused DD
or ERT2 induction domains in-frame at the N terminus, C terminus, or at both termini of the
PBase. For N terminal fusion proteins, an 18 amino acid linker sequence was included between
the PBase and the induction domain 88. For the C terminal fusion protein, a 24 amino acid linker
was added between the PBase and induction domain 16.
In order to evaluate these different fusion proteins, we needed a simple, robust way to
measure PB transposition. We adopted the commonly used method of co-transfecting cells with
two plasmids: a ‘helper’ plasmid expressing the PBase and a ‘donor’ plasmid carrying the PB
transposon with a drug-resistance marker 2. Once transfected into the host cells, the PBase
mobilizes the transposon from the donor plasmid and integrates it into the host genome,
conferring the cell with drug resistance. The number of drug-resistant colonies is closely
correlated with the number of transposon integration events and is a key indicator of the
efficiency of the PB transposon system 2, 16, 89. We used this system to measure, for each posttranslational control system, the absolute transposition efficiency of the activated construct
relative to the unfused piggyBac transposase, and the fold-induction achieved by each method in
four different cell lines. We then went on to optimize the most promising system, characterize
the dynamics of the temporal control achieved by the optimal system and evaluate the effects of
two of the inducer molecules on cellular transcription and function.
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Category

Construct ID and name

FKBP(DD)-based
helper constructs

DHFR(DD)-based
helper constructs

ERT2-based
helper constructs

Donor constructs

Construct structure

1. FKBP-PBase

CMV

2. PBase-FKBP

CMV

3. FKBP-PBase-FKBP

CMV

FKBP

4. NLS-FKBP-PBase

CMV

NLS FKBP

5. FKBP(2)-PBase

CMV

FKBP FKBP

PBase

6. FKBP(2)-PBase-FKBP

CMV

FKBP FKBP

PBase

7. FKBP-YFP-PBase

CMV

8. YFP-PBase

CMV

9. Cumate>iPBase

Cumate FKBP

10. DHFR-PBase

CMV DHFR

11. PBase-DHFR

CMV

12. DHFR-PBase-DHFR

CMV

13. ERT2-PBase

CMV

14. PBase-ERT2

CMV

15. ERT2-PBase-ERT2

CMV

pA

PBase

FKBP

FKBP pA

PBase

FKBP pA

PBase

YFP

FKBP

EF1

pA
DHFR pA
DHFR pA

PBase
ERT2

PBase

PBase

ERT2

puro)resistance$gene$
5’ TR

pA
ERT2

PBase

G F

RFP

FKBP IRES

PBase

PGK$

pA
pA

PBase

DHFR

17. PBSplitGFP

FKBP pA

PBase

PBase

5’ TR

pA

PBase

YFP

16. 5’LTR-puro-3’LTR

pA

PBase

3’ TR

pA
ERT2

pA

3’ TR

P

Figure 2.2 Schematic illustration of the constructs used in this study. For the helper
constructs: PBase, PiggyBac transposase; CMV, cytomegalovirus promoter; pA, bovine growth
hormone polyA signal. FKBP, a destabilizing domain derived from FK506 and rapamycin
binding protein. DHFR, a destabilizing domain derived from Escherichia coli dihydrofolate
reductase; YFP, yellow fluorescent protein; ERT2, mutated ligand-binding domain of the
estrogen receptor; Cumate, cumate operator (mutated cmv promoter). For the donor construct:
5’TR-puro-3’TR contains the minimal PB terminal repeats (5’LR and 3’TR) flanking a PGK
promoter driven puromycin resistance cassette; EF1, elongation factor 1 promoter; GFP, green
fluorescent protein.
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2.3.2 Evaluating the transposition efficiencies of inducible PBase
We first measured the transposition activity of the induced PBase fusion proteins relative to that
of unfused PBase. The transposition activity for each variant of helper constructs was obtained
by transfecting the above-mentioned four cell lines with an equimolar ratio of donor and helper
plasmids in the presence of chemical inducers (Shld1 for FKBP fusions; TMP for DHFR fusions;
4OHT for ERT2 fusions). Typical images of stained colonies from negative control, inducertreated and non-treated co-transfected experiments, and positive control with unfused PBase are
shown in Fig 2.3A. In our assays, the DD-based induction systems had significantly higher
activities than the ERT2-based induction system in all cell lines. The highest PBase activity was
observed for the constructs of FKBP-PBase and DHFR-PBase, both of which had activities that
were ~95% of “wild-type” levels. In contrast, all of the ERT2 fusion proteins displayed activities
less than 25% that of the unfused PBase. Thus, we conclude that, under inducing conditions, the
FKBP and DHRF DDs have little effect on PBase transposition activity while ERT2 appears to
significantly interfere with the PBase activity. For the two DD-based induction systems, the
transposition activities between N and C terminally tagged PBase fusions are not significantly
different (p>0.05). However, we observed a significant decrease of PBase activity when both
termini were attached to either DD, suggesting that at least one terminus should be exposed for
near-optimal PBase transposition activity.
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Figure 2.3 The performance of different helper constructs in DD and ERT2 based PB
transposon induction systems. (A) Typical images of colony forming and staining assays to
evaluate the transposition efficiency. The scale bar in the enlarged image equals 0.1mM. The
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construct used is FKBP-PBase. a) Cells transfected with donor and helper backbone plasmids
(yeast shuttle vector pRS314) were used to estimate the background or random insertions. b) and
c) Cells transfected with FKBP-PBase and donor plasmids either in the absence or presence of
Shld1 were used to evaluate the transposition efficiency. d) Cells transfected with unfused PBase
and donor plasmid were used to estimate the maximum transposition efficiency. (B) Induced
PBase activity of different PBase fusions relative to wild-type PBase across four cell lines. The
number of puromycin-resistant colonies formed from the cells transfected with both donor and
helper plasmids was normalized to that with donor and helper backbone plasmids prior to any
further calculations (background deduction). The induced transposition activity of an inducible
domain (i.e. FKBP, DHFR or ERT2) fused PBase was calculated as the normalized number of
colonies from the PBase fusion divided by that from “wild type” unfused PBase. Experiments
were done in triplicates. (C) Non-induced PBase activity of different PBase fusions across four
cell lines. Experimental conditions were the same as in B except that no drug was added for noninduced samples. (D) Fold induction of different PBase fusions across four cell lines. The
induction fold was calculated as the normalized number of colonies from chemical inducer
treated samples in B divided by that from untreated samples in C.

2.3.3 The FKBP DD system achieved the highest fold-change between induced and
uninduced states
We next sought to quantify how tightly the different induction systems regulated the PBase
protein. To do so, we again transfected the four cell lines with donor and helper plasmids;
however, in this assay, we omitted the small-molecule inducers. We found that the DHFR-based
PB induction system had a much higher background than did the FKBP and ERT2-based ones
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(Fig 2.3C). To determine which PBase fusion protein provided the largest dynamic range, we
used the corresponding induced and non-induced transposition rates to calculate the foldinduction for each protein (Fig 2.3D). This analysis revealed that the FKBP-based induction
system displayed a significantly higher fold-induction than both the DHFR and ERT2-based
systems in all cell lines (p<0.05). The FKBP-PBase-FKBP fusion protein showed the highest
fold-induction while the ERT2-PBase-ERT2 fusion protein showed the lowest. Taking foldinduction and the absolute activity of induced PBase into consideration, the FKBP-based
inducible PB transposon system outperformed its DHFR and ERT2-based counterparts.

2.3.4 HSP90 levels correlate with the dynamic range of the ERT2 system
The dynamic ranges of the ERT2 controlled PBase fusion proteins were highly variable
across the different cell lines (Fig 2.3D). For example, the PBase-ERT2 fusion displayed a 12fold change in transposase activity between induced and uninduced conditions in mouse RW4
embryonic stem cell, but a significantly lower fold-induction in the other cell lines (p<0.05). One
possible explanation for this observation is that the HSP90 protein is typically highly expressed
in mouse ES cells. HSP90 is the molecule that sequesters the fusion protein in the absence of
inducer, and it has been previously reported the HSP90 RNA 90 and protein 91 levels are
significantly higher in mouse ES cells than in differentiated cell lines or embryoid bodies. To
confirm HSP90 is indeed highly expressed in our mESCs, we performed RNA sequencing on the
RW4 and HCT116 lines. We found that the beta-actin normalized HSP90 expression level in the
RW4 mouse ES cell line was 4-fold higher than that in HCT116 cell line, which is consistent
with the theory that HSP90 levels explain the differences observed between RW4 mouse ESCs
and HCT116 cells.
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2.3.5 There is a trade-off between maximal PBase activity and fold-induction
In the FKBP-based induction system, the PBase fusion protein shuttles between the
cytoplasm where FKBP-directed degradation occurs and nucleus where PB transposition occurs.
Therefore, we hypothesized that this nucleo-cytoplasmic transport could be fine-tuned to create
an induction system with both efficient transposition and rapid degradation. To try to further
improve transposition efficiency, we fused the nuclear localization sequence (NLS) from the
SV40 large T-antigen upstream of, and in-frame with, the FKBP-PBase fusion, which had the
highest transposition activity in our previous tests (Fig 2.3B). We reasoned that the NLS should
direct more fusion protein to the nucleus, increasing the transposition rate upon administration of
Shld1. We used transient transfection to introduce an equimolar ratio of NLS-FKBP-PBase
fusion-carrying plasmid and donor plasmid across four different cell lines, and compared the
results to that of FKBP-PBase plasmid without the NLS. After induction, the engineered fusion
protein (NLS-FKBP-PBase) displayed an increase in transposition activity relative to the FKBPPBase fusion protein (Fig 2.4A, p<0.05). However, we also observed higher background
transposition in the uninduced sample for this construct. As a result, the fold-induction for the
NLS-FKBP-PBase fusion was lower than that of FKBP-PBase (Fig 2.4B, p<0.05). This suggests
that the NLS sequence sequesters some protein in the nucleus and prevents efficient degradation
in the absence of Shld1. Based on this observation, we concluded that adding NLS to PBase
fusion protein is not optimal for an inducible PB transposon system.
To test the possibility of further reducing the background transposition that occurs in the
absence of chemical inducer, we made two more fusion constructs. One contains two tandem
FKBP domains at the N terminus of PBase (Fig 2.2, construct 5) since our previous results
showed that an N-terminally tagged PBase was more tightly regulated than the corresponding C22

terminally tagged PBase. The second construct utilized three FKBP domains: two in tandem on
the N-terminus and one on the C-terminus (Fig 2.2, construct 6). We tested the transposition
efficiency and dynamic range of these constructs as before, and found that the triple FKBPs
fusion protein (FKBP-FKBP-PBase-FKBP) showed the highest fold-induction in all cell lines
(Fig 2.4A, right panel), followed by the double FKBPs fusion proteins (FKBP-PBase-FKBP and
FKBP-FKBP-PBase). All three constructs achieved a significantly higher fold induction than did
FKBP-PBase (p <0.05).
We next examined the maximal induced transposition efficiency of these constructs
relative to the unfused PBase (Fig 2.4B, right panel). We found that the transposition efficiencies
of FKBP-FKBP-PBase-FKBP, FKBP-FKBP-PBase, and FKBP-PBase-FKBP were 60%, 79%
and 80% of the unfused PBase, which is significantly lower than the 95% relative activity we
observed for FKBP-PBase (p<0.05), indicating that transposition activity gradually decreased
when more FKBP domains were added to PBase. Taken together, these results suggest that there
is a trade-off between the efficient degradation of the PBase fusions under non-inducing
conditions and the enzymatic activity of these fusions under fully inducing conditions (Fig 2.4C).
Specifically, if high activity upon induction is the objective, then the FKBP-PBase fusion is
optimal, while if a high fold-change in induction is required, the FKBP-FKBP-PBase-FKBP
fusion is the best choice.

23

Figure 2.4 Optimization of the induced transposition activity and fold induction for FKBPbased PB transposon induction system. (A) Induced transposition activity of different PBase
fusion proteins relative to wild-type PBase across four cell lines. Experiments were done in
triplicates. The induced transposition activity of a PBase fusion protein was calculated as the
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normalized number of colonies from the PBase fusion in the presence of corresponding chemical
inducer divided by that from “wild type” unfused PBase. (B) Fold induction of different PBase
fusion proteins across four cell lines. The induction fold was calculated as the normalized
number of colonies from chemical inducer treated samples divided by that from untreated
samples. (C) Comparison of the induced transposition activity with the fold induction for
different PBase fusion proteins across four cell lines.

2.3.6 Fusion protein levels can be tuned to achieve low background transposition and high
inducibility
For some application, it is not important to obtain the maximum possible PBase activity,
but it is instead preferable to have an assay with low background levels and to achieve a large
fold-change in activity upon induction. We reasoned that the high background levels observed in
Figs. 2.3 and 2.4 might be due to the fact that the PBase-DD fusion proteins were all highly
expressed and could be overloading the proteasome. To test this hypothesis, we created lentivirus
containing an FKBP-PBase-FKBP-IRES-RFP fusion gene under the control of a cumate
inducible promoter 92 (Fig 2.2, construct 9), which allows gene expression to be tuned by varying
the cumate concentration in the culture media. Next, we infected cymR expressing HEK 293
cells, and isolated transduced cells by performing FACS to purify RFP positive cells. We
transfected these cells with donor plasmid (Fig 2.2, construct 16), titrated FKBP-PBase-FKBP
protein levels by culturing the cell with varying amounts of cumate, in the presence or absence of
Shld1, and determined PBase activity by counting puromycin resistant colonies as previously
described. The results are shown in Fig 2.5. As lower concentrations of cumate were added to
the media, much lower background and larger fold-changes in induction were achieved. For
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example, when 10 ug/ml cumate was added to the media, no background transposition was
observed; therefore, we observed a more than 100-fold change in PBase activity is achieved after
induction with Shld1. These results demonstrate that, when the FKBP-PBase-FKBP protein is
expressed at moderate levels, this system has essentially no background transposition yet is still
robustly inducible. This level of control comes at some cost, however, as the maximum level of
PBase activity is roughly one-fourth the maximum rate we observed (i.e. compare the 10 ug/ml
cumate and Shld1 culture condition to the PBase activity of cells grown with 70 ug/ml cumate
and Shld1). For experiments that do not require rapid, post-transcriptional induction, it is
possible to have the best of both worlds, namely zero background and high absolute activity, by
growing cells in the absence of cumate and Shld1 and then adding both chemicals to induce
transposition.

Figure 2.5 The performance of cumate-regulated FKBP-based PB transposon induction
system. The cumate chemical ranging from 70 µg/ml to 0 µg/ml was added respectively to
regulate the strength of cumate promoter. For each cumate concentration, Shld1 or vehicle (70%
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ethanol) was added to the medium to activate the PB transposon induction system. The
normalized number of puromycin-resistant colonies was calculated by deducting the background
colonies from the transfection with donor and empty vector. The induction fold was calculated as
the normalized number of colonies from inducer treated samples divided by that from untreated
samples.

2.3.7 The FKBP-PBase-FKBP protein levels can be tuned post-transcriptionally
We next sought to determine if PB activity could be post-transcriptionally tuned by
adjusting Shld1 concentration. To do so, we transfected four cell lines with donor and helper
plasmids (Fig2.2, construct 3 and 16) and subjected these transfected cells to various
concentrations of Shld1: 0nM, 8nM, 40nM, 200nM and 1µM. We calculated the normalized
number of puromycin resistant cell colonies for each Shld1 concentration. We found that the
colony number increased almost linearly with the increase of the concentration across all cell
lines (r=0.81, Fig 2.6A), indicating the FKBP-based PB transposon induction is tunable and
dose-dependent.
Counting puromycin-resistant colonies reveals the number of cells with at least one
integrated transposon; however, it does not provide information about the average number of
transposition events that have occurred per cell. To address this, we also measured PBase activity
at various concentrations of Shld1 using an alternative readout for transposition. We created a
donor vector (Fig 2.2, construct 17) in which a GFP gene is split by a PB transposon, rendering it
inactive (Supplementary Fig. 2.S1A). Nuclear PBase will excise the transposon creating a
functional GFP gene that is then expressed, and so the average fluorescence of the cell
population is proportional to the number of transposon excision events. The results of these
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experiments are shown in Supplementary Figs. 2.S1B and 2.S1C. The mean cellular fluorescence
increases monotonically with Shld1 in a near-linear fashion, validating the results obtained with
the puromycin donor, and supporting the thesis that PB induction is tunable and dose-dependent.

2.3.8 The FKBP based PBase system is reversible
To determine if the degradation of FKBP-PBase is reversible, we fused a yellow
fluorescent protein (YFP) in-frame between FKBP and PBase by an 18 amino acid linker at N
terminus of PBase 88 (Fig 2.2, construct 7), allowing the visualization and semi-quantitative
analysis of the expression of the PBase fusion by monitoring fluorescence intensity. The four cell
lines mentioned above were transfected with the helper plasmid (FKBP-YFP-PBase) and
separately, a control plasmid (YFP-PBase). Shld1 was added to the culture medium immediately
upon transfection and incubated for one day. Next, the cells were passaged and cultured in drugfree medium for three days. Finally, Shld1 was added back again to re-stabilize the FKBP-YFPPBase fusion for another three days. The typical images from fluorescence microscopy at three
turning points were shown in Fig 2.6B: 1) one day after treatment with Shld1, 2) three days after
removing Shld1, and 3) three days after retreatment with Shld1. We also measured the
percentage of YFP positive cells every day by flow cytometry. To control for plasmid dilution
during the experiment, the percentages of YFP positive cells from the FKBP-YFP-PBase fusions
were normalized by the percentage of YFP positive cells in the corresponding control YFPPBase samples. The results are plotted in Fig 2.6C. Taking Fig 2.6B and 2.6C together, we
observed a sharp drop in the YFP positive cell population at the second measurement time point,
indicating that without the inducer Shld1, the fusion proteins were quickly degraded. The
normalized percentage of YFP positive cells was nearly completely restored to the original value
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three days after Shld1 was reapplied, indicating the system is reversible. By fitting the curves in
Fig 2.6C to an exponential decay functions, we estimated the half-life of the FKBP-PB fusion
protein to be 30h. Our results suggested FKBP-based inducible PB transposon system is tunable
and reversible. These levels of regulation could prove invaluable when a certain number of
transposition events is required in the induction system.
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Figure 2.6 Tunability and inducibility of the FKBP-based PB transposon induction system.
(A) Normalized puromycin-resistant colonies under different concentrations of Shld1 across four
cell lines. Cells were transfected with donor and helper plasmids (FKBP-PBase-FKBP) and
subjected to various concentrations of Shld1: 0nM, 8nM, 40nM, 200nM and 1µM. For each
condition, the number of puromycin resistant cell colonies was normalized to that from cells
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transfected with the donor plasmid and helper vector (pRS314). (B) Fluorescent images taken
prior to FACS analysis at day1, day4 and day 7 of Shld1 treatment for transfected HEK293T
cells. The white scale bar equals 50µm. The red arrows indicate the time points of measurement.
Bright field and fluorescent images were shown at top and bottom panel respectively. (C)
Normalized percentage of YFP positive cells along Shld1 treatment across four cell lines. A
minimum of 10000 YFP positive cells were analyzed from each FACS and post-sort analysis
was performed with FloJo software to obtain the percentage of YFP positive cells.

2.3.9 Unlike 4OHT, Shld1 does not interfere with general cellular functions
It has previously been reported that 4OHT adversely affects developmental processes such
as neurogenesis 84, myelinogenesis 84, myometrial differentiation 85, and sexual maturity 86.
Therefore, we next sought to test if cells treated with Shld1 or 4OHT display any developmental
phenotypes. We added these chemicals to embryoid bodies (EBs) generated from mouse ESCs,
and differentiated them into ventral spinal neural cells with retinoic acid and smoothened agonist
93

. We found that in the presence of 2µM 4OHT, EB differentiation was inhibited and neuron-

like cells were not generated. In contrast, EBs that were mock-treated or treated with 2µM Shld1
differentiated normally (Fig 2.7A). These results suggest that 4OHT inhibits EB differentiation,
while Shld1 does not.
To further explore the effects of the inducer molecules on differentiation, we sought to
quantify the extent to which these Shld1 and 4OHT perturb the transcriptional network of EBs.
EBs were treated with Shld1 and 4OHT respectively for 2 days, induced with retinoic acid and
smoothened agonist for 2 more days, and then subjected to gene expression profiling by RNASeq. Cells mock-treated with 95% ethanol as vehicle were used as controls. For each condition,
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two biological replicates were performed and correlation co-efficiencies between them are above
0.96, demonstrating reproducibility. The mean of the normalized counts from drug-treated
samples was plotted against log2 fold change of drug-treated samples to mock-treated ones under
the category of Shld1 vs Mock and 4OHT vs Mock (Fig 2.7B and 2.7C). A significant change of
gene expression profile was observed for 4OHT-treated samples but not in Shld1-treated ones.
After Benjamini-Hochberg correction for multiple hypotheses (see methods), we identified 260
differentially expressed genes in the 4OHT-treated samples. We performed gene ontology (GO)
analysis on these genes using the DAVID Bioinformatics package 94, 95 and functional annotation
clustering revealed that “heat shock” and “stress response” were the most over-represented terms
(adjusted p < 0.01), a result that supports our experimental observation that 4OHT is toxic to
EBs. In contrast, only one gene (FOS, NM_005252) was differentially expressed in the Shld1
treated samples, suggesting that this chemical has little to no effect on the transcriptional
network that controls development of EBs.
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Figure 2.7 The effects of chemical inducer on RW4 mouse ES cells. (A) Images of embryoid
bodies (EBs) and differentiated EBs treated with (a) 95% ethanol as vehicle, (b) 2µM Shld1 and
(c) 2µM 4-hydroxytamoxifen during EB formation and neural differentiation from mouse ESCs
to neural lineages. (B and C) The comparison of gene expression profile of drug-treated samples
with that of mock-treated ones. Experiments were done in duplicate. Mean of the normalized
counts from drug-treated samples was plotted against log2 fold change of drug-treated samples
to mock-treated ones under the category of (B) Shld1 vs Mock and (C) 4OHT vs Mock. Red dots
indicate the differentially expressed genes.
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2.4 Discussion
We systematically characterized, in four cell lines, 15 different PB transposase fusion
proteins representing 3 different induction systems. We found that the FKBP-based system
achieved the broadest dynamic range of induction across four cell lines. Remarkably, in the
presence of chemical inducer, this system had transposition efficiencies that were almost as high
(~95%) as the “wild-type” PB transposon. These results, coupled with the fact that Shld1 does
not affect ESC development, suggest that this will be the preferred induction system for many
types of experiments, especially those involving cellular differentiation or organismal
development.
In our plasmid-based experiments (Fig 2.3), we observed a lower dynamic range for the
ERT2-based PB transposon induction system that was previously observed by Cadinanos et al.
(~20 fold vs ~270 fold) 16. This discrepancy is explained by the fact that, in our donor plasmid,
the puromycin resistance gene is driven by a PGK promoter whereas in Cadinanos et al., the
puromycin resistance gene is promoterless and downstream of a splicing acceptor site. In that
system, only insertions in active genes will produced colonies, but in our system, all insertions
will produce resistant clones. This would explain why we observed more background
puromycin-resistant clones when the transposase was not induced since both studies normalized
to background and small absolute changes in the denominator can lead to large changes in the
calculated fold change.
The moderate background transposition of the DD induction system observed in our
plasmid experiments (Fig 2.3) was largely the result of the over-expressed fusion protein
overloading the cells’ proteasome system, since when the FKBP-fused PBase was placed under
the control of a cumate-titratable promoter and delivered at lower copy number, we observed no
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background transposition while still achieving robust transposition after induction. Since no
background hops were observed at several cumate concentrations, the fold-induction of the
system is not defined; we conservatively estimate it as > 100-fold.
An interesting difference between DD-based systems and the ERT2 based system is that
the performance of the DD systems was more uniform across the difference cell lines. We
hypothesize that this difference is due to the fact that the DD system uses the ubiquitinproteasome system (UPS) to constantly degrade FKBP-fused PBase. The UPS is a general
degradation machinery and uniformly expressed and works efficiently in all mammalian cell
types. In contrast, the ERT2-based induction system is dependent on a specific cytoplasmic
protein HSP90, a gene whose expression varies widely between cells. Our RNA sequencing data
showed that the HSP90 expression level in the RW4 mouse ES cell line is about 4-fold higher
than in the HCT116 cell line, suggesting that a low amount of HSP90 levels may lead to either a
high basal activity without induction or a low induced activation.
In the FKBP-based PB transposon induction system, we observed that N-terminally tagged
PBase (FKBP-PBase) has a higher fold induction than the C-terminally tagged counterpart
(PBase-FKBP), which may suggest that FKBP fused at the N terminus is more likely to be
exposed and thereby recognized by the proteasome than when fused to the C terminus. This
terminal specific higher activity may relate to the distribution of functional components of
PBase. It was reported that the PBase has a functional nuclear targeting signal in the 94 Cterminal residues 96. C-terminal fused PBase, therefore, is more likely to negatively affect the
nuclear translocation of the PBase protein, which in turn increases the likelihood of being
recognized and degraded by the proteasome in the cytoplasm. We also observed that fusing
additional DDs to the PB transposase increases the fold-change in activation between the
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induced and uninduced conditions. However, the addition of multiple DDs causes the absolute
activity of the induced protein to be significantly reduced, suggesting a trade off between how
tightly a protein can be regulated, and its maximum activity in the induced state. Our results
suggest that the FKBP-DD is optimal when a high level of PB transposition is preferred, while
FKBP-FKBP-PBase-FKBP is the choice when tight regulation is the priority.
The FKBP system will be likely prove considerably more useful than the ERT2 system for
the study of developmental processes, since we found that the ERT2 inducer tamoxifen is a
strong inhibitor of embryoid body differentiation. Our results are consistent with previous reports
that tamoxifen has deleterious effects on a number of developmental systems 84-86. In contrast,
we found that Shld1, the FKBP inducer, has no such phenotype, and furthermore, few
transcriptional changes were observed in our RNA-Seq analysis of embryoid bodies treated with
Shld1. Together, these results suggest that the FKBP DD system is preferable to the ERT2
system for experiments involving cellular differentiation.

2.5 Method
2.5.1 Plasmid construction
The plasmids that contain mutated destabilized domains, FKBP and DHFR, were
purchased from Addgene with ID 31763 and 29326 respectively. The PBase-ERT2 plasmid
(mPBase-L3-ERT2) was a kind gift from Dr. Bradley 16. The coding sequence of mPBase-L3ERT2 was sub-cloned into a yeast shuttle vector pRS314 containing CEN6, ARS, and TRP1 to
use “gap repair” cloning technique in yeast cells (Strathern and Higgins 1991). This engineered
yeast shuttle vector was used as a “parental” plasmid (pRM1056) to derive other variants of
PBase constructs by gap repair method 2. Briefly, PCR-generated sequences were cloned into
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linearized vectors by recognizing a 40 bp overlap at their ends. This 40 bp overlap can be
engineered by designing primers for amplification of the desired sequences. For example, to
replace the ERT2 sequence with the FKBP sequence, the pRM1056 plasmid was linearized by
restriction digestion that cut the plasmid within the ERT2 sequence. The FKBP sequence was
amplified with a pair of primers that have a 40bp sequence that is homologous to pRM1056. The
FKBP PCR products and linearized pBM1056 were co-transformed into yeast cells and the yeast
cells were selected for Trp+ colonies. DNA extracted from Trp+ yeast colonies was introduced
into E. coli. Finally, the plasmid was isolated by QIAprep Spin Miniprep Kit (QIAGEN) and was
confirmed by Sanger sequencing. The engineered constructs used in this study are depicted in
Fig 2.

2.5.2 Cell culture and neural differentiation
Human embryonic kidneys cell lines (HEK293 and HEK293T) and human colon
adenocarcinoma cell line HCT116 were maintained in Dubecco's Modified Eagle Media
(DMEM; Gibco) supplemented with 10% FBS. RW4 mouse embryonic stem cells (ESCs) were
cultured in complete media consisting of DMEM supplemented with 10% new born calf serum,
10% fetal bovine serum (FBS; Gibco), and 0.3 mM of each of the following nucleosides:
adenosine, guanosine, cytosine, thymidine, and uridine (Sigma-Aldrich). To maintain their
undifferentiated state, cells were also cultured in the presence of 1000 U/mL leukemia inhibitory
factor (LIF; Chemicon) and 20 mM β-mercaptoethanol (BME; Invitrogen) in flasks coated with a
0.1% gelatin solution (Sigma-Aldrich). Mouse ESCs were differentiated into ventral spinal
neural cells using a retinoic acid (RA) and smoothened agonist (SAG) induction protocol as
described 93.
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2.5.3 Cell transduction and transgenic cell line generation
All lentiviruses used for cell transduction were produced by the Hope Center Viral Vectors
Core at Washington University School of Medicine. A CymR-expressing HEK293 cell line was
made by transducing the cell with lentivirus containing the cumate operator repressor driven by
an EF1a promoter at a multiplicity of infectivity (MOI) of 20 to ensure that CymR is
overexpressed. Two days after transduction, neomycin was added to the culture medium
(500ng/ml) and maintained for 7 days. Then, the CymR-expressing HEK293 cell line was further
transduced with lentivirus containing an FKBP-PBase-FKBP-IRES-RFP fusion gene driven by a
cumate inducible promoter at MOI of 0.5 to favor single-copy integration. To obtain a pure
population, transduced cells were then sorted for red fluorescent protein (RFP) positive cells.

2.5.4 Cell transfection and drug administration
All plasmids used for the transfection of cells were prepared using EndoFree Plasmid Maxi
Kit (Qiagen) following the manufacturer’s protocol. About 105 cells were electroporated with a
total of 0.6 µg of DNA (0.1 µg helper plasmid and 0.5 µg donor plasmid) by the Neon
transfection system (Invitrogen) and plated to one well of a 6-well plate. Immediately upon
transfection, cells were treated with 1 µM 4-hydroxy tamoxifen (4OHT, Sigma) for the ERT2
based induction system, 1 µM Shld1 (Clontech) for FKBP based induction system, 10 µM
trimethoprim (TMP, Sigma) for the DHFR based induction system. Negative controls were
mock-treated with 95% ethanol as vehicle. For the transgenic cell line expressing inducible
PBase driven by a cumate promoter, only donor plasmid was used in transfection. Cumate
inducer (System Biosciences) was added at concentrations ranging from 70 µg/ml to 0 µg/ml to
regulate the strength of cumate promoter. For the purpose of reproducibility, experiments were
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done in triplicates. To select cells in which the PB transposon transposed, cells were trypsinized
2 days after transfection and cultured on 10cm dish (Corning) with 10 ml fresh media containing
puromycin (1 µg/ml). The puromycin selection normally takes 7 days before visible cell colonies
are formed.
For experiments testing the reversibility of the FKBP-based PB transposon system, Shld1
(1 µM) was added to the culture medium immediately after transfection. One day after
transfection, a small aliquot of cells were used for imaging and flow cytometry analyses and the
rest of the cells were passaged to a 12-well plate and provided fresh Shld1-free medium. The
passaged cells were grown to about 100% confluence before another passage to a 12-well plate.
One well of cells were used for imaging and flow cytometry analyses every day. After 3 days of
destabilization, the cells were treated with fresh medium containing 1 µM Shld1 to re-stabilize
the FKBP-YFP-PBase fusion protein. The re-stabilization lasted for another 3 days during which
the cells were analyzed by flow cytometry every day.

2.5.5 Cell colony staining and counting
The visible drug-resistant cell colonies were fixed with PBS containing 4%
paraformaldehyde for 1 hour and then stained with 1% methylene blue in 70% EtOH for 30 min,
washed in distilled water and air-dried overnight. Colonies with diameters more than 0.3 mm
were counted by ImageJ software (National Institutes of Health). The number of puromycinresistant colonies formed from the cells transfected with both donor and helper plasmids was
normalized to that with donor and helper backbone plasmids (yeast shuttle vector pRS314) prior
to any further calculations. The transposition activity of a PBase fusion protein was calculated as
the normalized number of colonies from the inducible domain (i.e. FKBP, DHFR or ERT2)
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fused PBase divided by that from “wild type” unfused PBase. For experiments that used the
transgenic cell line expressing FKBP-PBase-FKBP driven by a cumate promoter, we used
normalized number of puromycin-resistant colonies to estimate the transposition activity due to
the unavailability of the cell line expressing “wild-type” unfused PBase. Fold-induction was
calculated as the normalized number of colonies from the induced samples divided by that from
untreated samples.

2.5.6 Imaging and flow cytometry
Fluorescent images were taken on Zeiss Axioskop fluorescence microscope equipped with
a QICAM FAST 1394 digital CCD camera. Cells were grown to 90% confluence, trypsinized
from the plate, and suspended in phosphate-buffered saline (PBS), washed once with PBS, and
resuspended in Hank’s balanced salt solution supplemented with 2 mM EDTA. Cellular
fluorescence was analyzed on an iCyt Reflection HAPS2 cell sorter at the Washington
University Siteman Flow Cytometry Core. The gate was set relative to the cells transfected with
non-fluorescent control plasmids to eliminate background. Cells transfected with a positive
control fluorescent reporter plasmid were also used to eliminate false positive singles. About
10000 cells were analyzed from each FACS and post-sort analysis was performed with FloJo
software to obtain the percentage of fluorescent positive cells.

2.5.7 RNA extraction and sequencing
Total RNA was isolated from the RW4 mouse ESCs using the PureLink RNA Mini kit
(Ambion) according to the manufacturer's instructions. The quantity of RNA was measured
using a spectrophotometer (NanoDrop 2000c; Thermo Scientific). Samples with a RNA
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concentration (A260/A280 ≥1.8 ng/µl) and purity (A230/A260 ≥2.0 ng/µl) were selected. The
Agilent 2100 Bioanalyser was used to determine the RNA integrity number (RIN). The
degradation level was identified using the RNA 6000 Nano LabChip kit (Agilent). Samples with
RIN >9.8 were further processed using TruSeq mRNA Library Preparation Kit (Illumina) and
then sequenced by Illumina MiSeq platform at the Genome Technology Access Center (GTAC)
at Washington University in St. Louis. The gene expression data generated for this study can be
found under the NCBI Gene Expression Omnibus (GEO) accession number GSE78857. The
expression data is also publically available at the Center for Genome Sciences by request.

2.5.8 Reads mapping and statistical analysis
Trimmomatic (v0.32) 97 was employed on RNA-Seq FASTQ files to clip the illumina
adaptors and remove the reads of low quality. The cleaned reads were mapped back to mm10
genome reference from UCSC database using STAR (v2) 98. We used the HTSeq package99 to
estimate the count of uniquely mapped reads for each of the annotated genes in the mm10 gene
transfer format (.GTF) file. Differential expressed genes were analyzed with R (v 2.13.0) using
DESeq (v1.4.1) 100 available in Bioconductor (v 2.8). The resulting p-values were adjusted using
the Benjamini-Hochberg correction and only genes that were significant at a false discovery rate
(FDR) of 0.05 were considered as expressed. For other comparisons between different
experimental conditions, the statistical significance was assessed by paired Student t test and a p
value less than 0.05 was considered significant.
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Chapter 3
Brd4-bound enhancers drive critical sex
differences in glioblastoma
Published in BioRxiv. (2018)

3.1 Abstract
The incidence and severity of many diseases is strongly dependent on sex. New approaches
to treatment could be revealed by dissecting the molecular pathways that control sexually
dimorphic phenotypes. In an established model of glioblastoma, we discovered that
pharmacological inhibition or genetic depletion of Brd4 decreased clonogenicity and
tumorigenicity in male cells while increasing clonogenicity and tumorigenicity in female cells,
thus abrogating the sex differences in phenotype. The sex differences in tumorigenic phenotype
correlated with transcriptome-wide sexual dimorphism in gene-expression, H3K27ac marks and
large Brd4-bound enhancers. Finally, sexual dimorphism in Brd4 function was also suggested by
the differential effect of low Brd4 expression on survival in glioblastoma patients. Thus, for the
first time, sex is established as an intrinsic element of cellular identity that is driven by Brd4
activity, which renders male and female cells differentially sensitive to BET inhibitors treatment.
This has important implications for the clinical use of BET inhibitors and provides new molecular
targets for glioblastoma treatment.
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3.2 Introduction
Until recently, most basic and clinical research has focused on investigating factors that
influence disease susceptibility and progression without regard to sex. However, a mounting
body of evidence has revealed significant sex-specific differences in incidence, age of onset,
and outcome of numerous human diseases. These include cardiovascular diseases, asthma,
autoimmune diseases, birth defects, neurological diseases, psychiatric disorders and cancers 101.
This preponderance of sex differences in disease incidence and outcome led to the
implementation of new guidelines by the NIH regarding inclusion of sex as a biological
variable in all research.
Glioblastoma (GBM), the most common and aggressive form of brain cancer 102, 103, is
more common in males regardless of race or region of the world (male to female incidence of
1.6:1) 104-107. In addition to the sex difference in GBM incidence, a recent study by Ostrom et al.
also revealed a sex difference in prognosis between male and female GBM patients wherein
females have a significant survival advantage 108. The reasons for sex differences in GBM
incidence and outcome are largely unknown. While sex differences in disease are often
mediated through acute sex hormone actions, sex differences in malignant brain tumor rates are
evident at all ages, suggesting that factors other than circulating sex hormones underlie this
discrepancy 109. These can include organizational or epigenetic effects of transient in utero sex
hormones and extra-gonadal effects of sex chromosome encoded genes. Recently, our lab
discovered that an established model of GBM involving combined loss of neurofibromin (NF1)
and p53 function in murine neocortical astrocytes exhibits sex differences in in vivo
tumorigenicity mimicking those observed in patients with GBM 19. Importantly, these male and
female GBM astrocytes display sex differences in response to serum deprivation, CDKi
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treatment and chemotherapy 110. Together, the human and mouse data suggest that male and
female cells may be differentially sensitive to the transforming effects of specific oncogenic
events.
Sexual differentiation is in large part an epigenetic phenomenon 111. A preponderance of
studies have shown that inhibiting epigenetic modifiers can block normal sexual dimorphism in
the brain. Understanding whether sex differences in GBM are mediated by epigenetic
mechanisms involving epigenetic readers and/or writers will be imperative to understanding the
key processes that impart females with relative resistance and males with relative susceptibility
to cancer. Here we show that the previously observed phenotypic differences between male and
female GBM cells are abolished by targeting the Bromodomain and extra-terminal (BET)
family proteins using a panel of BET inhibitors currently in clinical trials 112. Genetic depletion
of the BET family members indicated that the effects are mediated by the epigenetic reader
Brd4. Mapping of Brd4 genomic localization revealed that sex differences in tumor phenotype
arise through differential Brd4-bound enhancer usage in male and female GBM cells.
Consistent with these data, we observe sex differences in the effects of low Brd4 expression on
survival in male and female GBM patients. This is the first demonstration that differential Brd4
activity mediates cell intrinsic sex identity and sex differences in a cancer phenotype. Together
with sex differences in BET inhibitors effects, these results strongly indicate that sex
differences in disease biology translate into sex differences in therapeutic responses. This has
broad implications for medicine.
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3.3 Results and discussion
3.3.1 BET family protein (Brd4) inhibition has opposing effects on the tumorigenic
phenotype in male and female GBM astrocytes
Based on our previous observation of sex-specific differences in the tumorigenic
phenotype and response to chemotherapy between male and female GBM cells 19, we first
sought to investigate whether these GBM astrocytes also exhibit sex-specific treatment
responses to BET inhibitors currently in clinical trials. We treated male and female GBM
astrocytes with a panel of BET inhibitors that are presently being tested in clinical trials and
then performed extreme limiting dilution assay to measure clonogenic cell (stem-like cell)
frequency (ELDA). These BET inhibitors are either selective for Brd4 or target all members of
the Brd family. Treatment with BET inhibitors reproducibly decreased clonogenic frequency in
male GBM cells while increasing the functional clonogenic cell fraction in female cells (Figure
3.1A). Next, and to determine which BET family protein was mediating these effects, we
performed genetic depletion of Brd2, 3 and Brd4 family members. We used shRNAs specific to
either Brd2, Brd3 or Brd4 then evaluated the effect on the tumorigenic phenotype of male and
female GBM cells. As shown in Figure 3.1C, mRNA expression levels of Brd2, Brd3 and Brd4
were partially silenced in male and female GBM cells after infection with lentiviral shRNAs. Of
note, Brd4 mRNA4 levels were equivalent between male and female GBM cells under basal
conditions. Knockdown of Brd2 with shRNAs did not affect clonogenic frequency in either
male or female cells, which is consistent with our earlier RVX-208 (a Brd2/3 selective
inhibitor) results (Figure 3.1B). Interestingly, male GBM cells with knockdown of Brd4
exhibited a decrease in clonogenic frequency whereas female cells displayed an increase in
clonogenic frequency. This opposing sex-specific response to the inhibition of Brd4 is
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consistent with published data in breast and prostate cancer, wherein ectopic expression of Brd4
in breast cancer cells decreased invasiveness and tumor growth, while Brd4 inhibition
decreased viability of prostate cancer cells 113-115. A similar effect on clonogenic frequency was
observed following knock down of Brd3 in male but not female cells.
To investigate the effect of Brd2, 3 and 4 expression on sex-specific survival outcomes in
human GBM, we obtained gene expression data from 151 (98 males and 53 females) TCGA
glioblastoma samples, converted the expression value of Brd into a z-score specific to the sex of
the patient and stratified the patients into a high-expression group (z-score > 1.0) and lowexpression group (z-score < -1.0). We analyzed the effects of Brd expression on patient overall
survival (OS) using the Kaplan-Meier method 116. No difference in survival was detected in
low Brd2 or Brd3 expression groups (data not shown). While high Brd4 expression group had
no effect on survival, low Brd4 expression was associated with shortened survival in females
(OS median - 5.39 months) compared to males (OS median - 16.59 months, p = 0.05) (Figure
3.1D). This is consistent with our findings in our mouse GBM model, in which treatment with
the BET inhibitor abrogated the tumorigenic phenotype in male cells, but enhanced it in female
cells. Additionally, this data is consistent with previously published breast, endometrial and
prostate cancer studies revealing that in women with estrogen receptor positive breast cancer 113
or endometrial cancer 115 low Brd4 expression is correlated with worsened survival. This is in
contrast to men with prostate cancer in whom low levels of Brd4 are associated with improved
survival 114, 115. Altogether, and with the multitude of evidence for the deregulation of Brd4 in
numerous cancers, these data affirm a role of Brd4 as a mediator of sex differences in GBM
tumorigenic phenotype.
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Figure 3.1 Brd4 inhibition has opposing effects on the tumorigenic phenotype in male and
female GBM astrocytes. (A) Clonogenic cell frequency (ELDA) assays were performed in
GBM cells treated with DMSO or BET inhibitors. BET inhibitors significantly reduced
clonogenic cell frequency in male cells while female cells exhibited a significant increase in
their stem-like cell frequency. Clonogenic cell frequency were unaffected by RVX-208, a
Brd2/3 selective antagonist. (B) Clonogenic cell frequency assays were performed in shRNA
knockdown and control GBM cells. Knockdown of Brd4 and Brd3, but not Brd2, suppresses
clonogenic frequency in male GBM cells while female cells showed an increase in clonogenic
frequency following Brd4 knockdown only. Brd2 depletion was without effect. All treatment
groups were normalized to male control clonogenic frequency levels (*=p <0.05, **=p <0.01,
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***=p <0.001, ****=p <0.0001 as determined by two-tailed t-test and one-way ANOVA). (C)
Low expression of Brd4 has sex-specific effects on GBM patient survival. Female GBM
patients with low Brd4 expression (z-score < -1.0) have decreased survival, (median OS - 5.39
months), compared to male GBM patients with low Brd4 expression (z-score < -1.0, median OS
- 16.59 months; p=0.05).

3.3.2 Male and female GBM cells utilize different sets of Brd4-bound enhancers
In order to understand the role played by Brd4 in mediating sex differences in GBM, we
sought to map Brd4 genomic localization in male and female GBM astrocytes (highly active
Brd4-bound enhancers and typical Brd4 bound enhancers). Highly active Brd4-bound
enhancers have been shown to play key roles in establishing cell-identity and thus may be
important in establishing sex differences. Furthermore, these enhancers bind up to 90% of Brd4
protein in the cell 47, 117-121. Brd4 is an epigenetic reader that binds acetylated histones H3 and
H4 throughout the entire cell cycle and is known to be deregulated in numerous cancers 122.
Brd4 is thought to play a central role in cancer by promoting epithelial-to-mesenchymal
transition, stem cell-like conversion, and pluripotency 31, 123, 124, and the pharmacological
inhibition of this protein has shown therapeutic activity in a number of different cancer models
32, 112, 114, 125, 126

. To investigate whether these highly active Brd4-bound enhancers might play a

role in establishing cell-intrinsic sex differences, we used transposon Calling Cards 2, 78 to
identify enhancers differentially bound by Brd4. To do so, we fused a piggyBac (PB)
transposase to the C terminus of the Brd4 protein, endowing it with the ability to direct the
insertion of the PB transposon into the genome close to Brd4 binding sites. Three biological
replicates were carried out and the correlation between replicates was r > 0.9 for all pairwise
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comparisons (Figure 3.S1). Using this protocol, we mapped ~700,000 unique insertions
directed by the Brd4-PBase fusion for male and female samples and identified 3014 enhancers
that bound significantly more Brd4 protein in males and 3122 enhancers that bound
significantly more Brd4 protein in females (Figure 3.2A).
To determine whether the enhancers that bound Brd4 in a sex specific manner also
displayed differential H3K27ac, we performed Chromatin Immunoprecipitation Sequencing
(ChIP-seq) in male and female GBM cells to identify genomic regions enriched for H3K27
acetylation, a well-known marker of active enhancers. Three biological replicates were carried
out and the correlation between replicates was r > 0.9 for all pairwise comparisons (Figure
3.S1). Using established methods 127, we identified a total of 48881 and 51232 H3K27acenriched peaks in male and female GBM cells respectively. Of these, 10861 (22%) were malespecific and 13212 (26%) were female-specific (Figure 3.2B). We then performed differential
analysis between male and female cells and identified an additional 15976 differentially
H3K27ac-enriched regions, as depicted in the heat map clustered by male and female (Figure
3.2D).
Next, we analyzed the distances of sex-specific Brd4 binding sites to the nearest sexspecific H3K27ac-enriched enhancer regions. As shown in Figure 3.2E and F, sex-specific
Brd4 binding sites are significantly enriched at sex-specific H3K27ac enhancer regions (p <
0.01). Representative examples of two biologically relevant loci, Nkx2.1 and Zic1/4, which
correspond to male-specific and female-specific Brd4-marked enhancer regions respectively,
are depicted in Figure 3.2G and H. This is the first demonstration of differential Brd4-bound
enhancer usage by male and female cells of any kind and is consistent with earlier observations
that these enhancers are key regulators of cell identity and fate 47, 117, 118, 121, 128.
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Using sex-specific Brd4 binding sites that correlated with sex-specific H3K27ac-enriched
enhancer regions within 1kb distance, we identified the closest upstream and downstream genes
from the center of the Brd4 binding sites. This analysis revealed 351 male-specific genes and
384 female-specific genes. Pathway enrichment analysis on male-specific genes regulated by
these sex-specific Brd4-marked enhancers revealed functional enrichment for glioma, neoplasm
metastasis, metabolism, cell proliferation, chromosome aberrations and integrin signaling.
Similar analysis on female-specific genes showed an enrichment in pathways involved in
regulation of metabolic process, DNA repair-deficiency disorders, and semaphorin signaling
(Table 3.S1).
Based on our observation of sex-specific enhancers usage between male and female GBM
cells 19, we sought to characterize the male and female transcriptome. We profiled male and
female GBM cells with RNA sequencing (RNA-seq). For each condition, three biological
replicates were performed; the data were highly reproducible (Pearson r ³ 0.96 for all pairwise
comparisons) (Figure 3.S1) and indicated differential expression of 3846 transcripts (FDR <
0.05) (Figure 3.2I). Pathway enrichment analysis for the top 400 differentially regulated genes
was performed using a combination of KEGG pathway and Genomatix Pathway System
(GePS). Classification of these genes according to function revealed a significant number of
relevant and important pathways including cell differentiation, cell proliferation, glioblastoma,
tumor angiogenesis, metabolism, and DNA binding-transcription factors (Table 3.S2). Thus,
there are global differences in male and female GBM cell transcriptomes in cancer relevant
pathways, which are due to differences in sex-specific enhancer activity.
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Figure 3.2 Male and female GBM cells have sexually dimorphic Brd4-bound enhancers. (A)
3014 male-specific and 3122 female-specific Brd4-enriched peaks were identified. (B) 10861
male-specific and 13212 female-specific H3K27ac-enriched peaks were identified. (C) Heatmap
of Brd4 binding affinity (number of insertions) for sex-specific Brd4 binding sites in male and
female GBM cells (D) Heatmap of H3K27ac signal intensity (read depth) for sex-specific
H3K27ac-enriched regions in male and female GBM cells. Samples are clustered first by sex,
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then by replicate. Heatmap and intensity plot of the H3K27ac signal among sex-specific Brd4
binding sites (+/- 10kb from the center) in male (E) and female (F). The expression values of the
nearest gene(s) from the corresponding Brd4 binding sites was also plotted side by side. (G)
Nkx2.1 and (H) Zic1/4 illustrate male and female-specific genes, respectively, associated with
differential Brd4 binding affinity and H3K27ac enrichment. The x-axis (blue arrows) of all tracks
corresponds to genomic location of the gene. The y-axis of Calling Card tracks represents the
log10 scale of sequencing reads for each insertion as indicated by circles. The y-axis of ChIP-seq
tracks represents the number of uniquely mapped reads). (I) RNA abundance (RNA sequencing)
in male and female GBM cells (top 200 upregulated and 200 downregulated male/female genes
(n=3)).

3.3.3 Brd4-bound enhancers regulate sex differences in GBM
To further validate the transcriptional activation of sex-specific regulatory genes and
networks by Brd4-bound enhancers, we treated male and female GBM cells with the Brd4
antagonist JQ1. JQ1 is a thieno-triazolo-1,4-diazepine that displaces Brd4 from chromatin by
competitively binding to the acetyl-lysine recognition pocket 112, 125. Treatment of acute
myeloid leukemia cells with JQ1 caused a rapid release of Mediator 1 (Med1) from a subset of
enhancer regions that were co-occupied by Brd4, leading to a decrease in the expression of
neighboring genes 129. To investigate the functional activity of Brd4 at sexually dimorphic
enhancer sites regulating expression of cancer-relevant genes, we treated male and female GBM
cells with either vehicle (0.05% DMSO) or 500 nM JQ1 for 24 hours, and then isolated
genomic material for RNA-seq. Gene expression analysis on JQ1 treated cells revealed that
Brd4 proximal genes are significantly downregulated compared to genes that are distal to Brd4
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binding sites (p <0.01) indicating that JQ1 has a specific and directed effect on genes whose
expression is driven by Brd4-bound enhancers (Figure 3.3 and 3.4). Pathway analysis for sexspecific Brd4-bound enhancers’ genes downregulated following JQ1 treatment in male and
female GBM cells revealed functionally important pathways such as cancer stem cell pathway
regulated by sex-specific Brd4-bound enhancers (Table 3.S1 and Figure 3.5).

Figure 3.3 Male and female GBM cells have sexually dimorphic Brd4-bound enhancers and
concordant gene expression. Sex specific and shared Brd4-bound enhancers are analyzed under
the data category of 1) number of insertions from Calling Card method, 2) H3K27ac signal from
ChIP-seq, 3) expression value from nearest gene(s) from RNA-seq and 4) expression changes
(log2) upon JQ1 treatment.
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Figure 3.4 JQ1 effect on gene expression in Male and female GBM cells. (A)Heatmap of gene
expression changes (log2) upon JQ1 treatment in male and female GBM cells (B) Boxplot of
gene expression changes (log2) of Brd4 proximal and distal genes following JQ1 treatment of
male and female mouse GBM cells. The gene expression profile of genes in close proximity to
Brd4 binding sites is compared to distal genes by a Mann-Whitney-Wilcoxon test. Brd4 proximal
genes are significantly downregulated compared to Brd4 distal genes in both male and female
GBM cells following JQ1 treatment.
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Figure 3.5 Stem cell pathways regulated by sex-specific Brd4-bound enhancers. Bluelabeled genes are male-specific Brd4 bound enhancer regulated genes and red-labeled genes are
female-specific Brd4 bound enhancer regulated genes. As depicted, male-specific genes include
oncogenes such as Met, Myc and Sox2 while female-specific genes consist of tumor
suppressors such as Six 2 and Six 3.

We next integrated our Brd4 Calling Cards, H3K27ac ChIP-seq and RNA-seq data to
identify a set of sex-specific, Brd4 enhancer regulated genes. Candidate genes were identified
by proximity to both a sex-specific Brd4 binding site and a sexually dimorphic H3K27ac
enhancer region, and sensitivity to JQ1 (downregulation). These analyses identified 34 malespecific genes and 30 female-specific genes, which we refer to as sex-specific JQ1-sensitive
genes. Similar to our previous pathway analyses, male-specific JQ1-sensitive genes
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demonstrated functional enrichment for neoplasm metastasis, tumor angiogenesis, integrin
signaling pathway, and metabolic process, in addition to DNA-repair-deficiency disorders.
Female-specific JQ1-sensitive genes showed an enrichment in pathways involved in
semaphorin signaling, chromosome aberrations, glioblastoma, regulation of transcription, and
glucose metabolism disorders (Table 3.1). These results are indicative of sex-specific
transcriptional programs regulated by Brd4-bound enhancers. Identifying which specific
pathways are critical to sex differences in GBM will require further functional studies.
To address the sex-specific effects of BET inhibitors treatment on in vivo tumorigenesis,
we performed in vivo flank implantation studies. Based on our in vitro ELDA studies, we chose
to use JQ1 and CPI0610, the two BET inhibitors with the most dramatic effect in male and
female GBM astrocytes respectively. Each mouse received DMSO, JQ1 or CPI treated male
(5000 cells) or female cells (1.5 million cells) injected in the flanks and tumor growth was
monitored blindly for 7-12 weeks with thrice weekly micrometer measurements in 3
dimensions. Flank implantation of JQ1-treated transformed male cells produced smaller and
less number of tumors than control DMSO male implants (Figure 3.6). This effect was not
observed with CPI0610-treated transformed male cells. Importantly, CPI0610-treated
transformed female cells produced larger and more tumors than control DMSO female implants
(Figure 3.6). This effect was seen following only one dose of BET inhibitors prior to
implantation, indicating that this robust response is maintained and manifested at the epigenetic
level. Taken together, these results demonstrate for the first time that the sex differences in the
tumorigenic phenotype we observe in GBM cells are mediated by differential Brd4-marked
enhancers, and that the response to BET inhibition is sex-dependent.
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Table 3.1 Pathway analysis for sex-specific highly Brd4-bound genes downregulated
following JQ1 treatment male and female GBM cells.
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Figure 3.6 BET inhibitors have opposing effects on in vivo tumorigenicity in male and
female GBM astrocytes. (A) Representative flank tumors from DMSO or CPI0610 treated
transformed female GBM astrocyte-initiated tumors. (B) Male tumors were significantly
inhibited in their in vivo growth following JQ1 treatment compared to DMSO treatment (ChiSquare Fisher’s exact test p <0.0055). CPI0610-treated transformed female cells significantly
produced larger and more tumors than control DMSO female implants (Chi-Square Fisher’s
exact test p <0.0476).

In conclusion, these data demonstrate for the first time that cell intrinsic sex identity is
mediated by sex differences in Brd4-marked enhancer usage. In the model utilized here, the
differential usage of Brd4-bound enhancers mediated important sex differences in a GBM
tumorigenic phenotype. Additionally, the response to BET inhibitors treatment was shown to be
sex-dependent. Altogether, the consistency between our mouse data, the GBM TCGA data, and
published breast and prostate cancer studies, provides strong evidence for the context58

dependent, sex-specific dual role of Brd4 in regulating gene expression programs in
oncogenesis. Since bromodomain inhibitors are currently being evaluated in a number of
clinical trials, understanding this phenomenon is of critical importance, both for the
interpretation of existing trials and to guide better application of these drugs. Increasing our
knowledge of these sex-specific genetic and epigenetic mechanisms will lead to a greater
understanding of cancer biology and its relationship to normal development, as well as identify
novel therapeutic targets to improve outcome for all patients with GBM and potentially other
cancers that exhibit substantial sex differences in incidence or outcome.

3.5 Methods
3.3.1 RNA-sequencing
Male and female GBM cells (Nf-/-;DNp53 astrocytes) were generated as previously
reported (Sun et al., 2015) and grown in DMEM/F12 media supplemented with 10% FBS and
1% penicillin-streptomycin. Total RNA was isolated from male and female GBM cells that
were treated with DMSO (0.05%) or JQ1 (500 nM for 24 hours) using the RNeasy Mini Kit
from Qiagen, following the kit protocol (Hilden, Germany). PolyA Selection was performed to
create RNA Seq libraries. Cell mRNA was extracted from total RNA using a Dynal mRNA
Direct kit. The quantity of RNA was measured using a spectrophotometer (NanoDrop 2000c;
Thermo Scientific). Samples with an RNA concentration A260/A280 ≥1.8 ng/µl, and purity
A230/A260 ≥ 2.0 ng/µl were selected. The Agilent 2100 Bioanalyzer was used to determine the
RNA integrity number. The degradation level was identified using the RNA 6000 Nano
LabChip kit (Agilent). Samples with RNA integrity number > 9.8 were further processed using
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TruSeq mRNA Library Preparation Kit (Illumina) and then sequenced on a HiSeq 25000
(Illumina).

3.3.2 Chromatin immunoprecipitation sequencing (ChIP-seq) for H3K27ac
Male and female GBM cells were grown to 50% confluence (200K cells/T25 flask). On
the day of transfection and 30 minutes before applying complexes, media was replaced with
DMEM without FBS and antibiotics. Transfection complexes containing 3 µg of PB helper
DNA with a PB-Brd4 fusion and/or 3 µg of PB donor DNA with a puromycin selection marker
and Lipofectamine LTX/Plus Reagent (Invitrogen) were applied to cells for 12-18 hours at a
culturing condition of 37 °C and 5% CO2. Cells were then allowed to recover in fresh medium
containing DMEM/F12 with 10% FBS and 1% penicillin-streptomycin for another 24-48 hours.
Cells were then expanded into T75 flasks and selected using puromycin at a concentration of
2.5 µg/ml for 3 days. DNA was extracted from puromycin resistant cells and processed by
transposon calling card protocol as previously described 2. Briefly, DNA sample was divided
into three 2-mg aliquots, each digested by MspI, Csp6I, or TaqI individually. Digested DNA
was ligated overnight at 15°C in dilute solution to encourage self-ligation. After ethanol
precipitation, self-ligated DNA was resuspended in 30 ml ddH2O and used as template in an
inverse PCR. Primers that anneal to PB donor sequences were used to amplify the genomic
regions flanking PB, and adapter sequences that allow the PCR products to be sequenced on the
Illumina genome analyzer were added. The PCR products were purified using the QIAquick
PCR purification kit (Qiagen) and diluted into 10 nM concentration. For each sample, the same
amount of PCR product from digestion with each restriction endonuclease was pooled and
submitted for Illumina sequencing (HiSeq 2500).
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3.3.3 Sequencing data alignment and analysis
RNA-seq data sets were aligned to the transcriptome and the whole-genome with STAR
98

. Genes or exons were filtered for just those that were expressed. A gene count table for all the

genes in each sample was generated using HTSeq 99. Differential gene expression between pairs
of samples was computed using DESeq2 and was filtered by FDR < 0.05 for differentially
expressed genes 130.
ChIP-seq data sets for H3K27ac were aligned to the murine genome build mm10 using
Bowtie2 and only uniquely aligning reads were used 131. Regions of enrichment of H3K27ac
over background were calculated using the MACS version (2.1.0) peak finding algorithm 127.
An adjusted p-value threshold of enrichment of 0.01 was used for all data sets. The resulting
peak files were used as inputs for DiffBind (version 3.5) to derive consensus peak sets 132, 133.
The differential enrichment of H3K7Ac signals between male and female analysis was carried
out with Diffbind using DESeq2 (method = DBA_DESEQ2) with libraries normalized to total
library size.
Transposon calling cards data sets were aligned to the murine genome build mm10 using
Bowtie2 131. The Brd4 binding site was identified by using an established algorithm 2. Briefly,
the Brd4-directed PB insertions were clustered using a hierarchical clustering algorithm to
identify insertions within 2500 bp and then modeled as a Poisson distribution, with the number
of independent insertions in the “transposase-alone” experiment in the same genomic window
setting the expectation. The p-value is then calculated from cumulative distribution function
given the observed number of independent insertions in the Brd4-directed experiment.
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To identify the sites with an excess of Brd4 insertions in male GBM cells relative to
female cells, we used the algorithm from ChIP-Seq peaks caller MACS 127 but modified for the
analysis of calling card data. First, the transposon insertions were grouped by hierarchical
clustering. Then, peaks with an excess of insertions in the male sample were identified by
computing lambda, the number of insertions per TTAA expected from the female sample by
taking the maximum lambda calculated from the number of insertions in the female peak, or in
a 1kb, 5kb or 10kb window centered at that peak. We computed a p-value based on the
expected number of insertions (lamda × number of TTAAs in peak × number of insertions in
peak). To identify the sites with an excess of Brd4 insertions in female GBM cells relative to
male cells, we performed the same analysis, substituting the male and female data sets.

3.3.4 Pathway analysis
Pathway enrichment analysis for differentially regulated genes was performed using a
combination of KEGG pathway and Genomatix Pathway System (GePS). GePS uses
information extracted from public and proprietary databases to display canonical pathways and
or to create and extend networks based on literature data. These sources include NCI-Nature
Pathway Interaction Database, Biocarta, Reactome, Cancer Cell Map, and the ENCODE
Transcription Factor project data. All data for pathway analyses are presented with adjusted
corrected p-values.

3.3.5 Growth assays
Growth kinetics of male and female GBM cells (Nf-/-;DNp53 astrocytes) treated with
DMSO (0.05%), JQ1 (500 nM), or RVX-208 (5µM) for 24 hours or shRNAs were examined by
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counting live cell number using an automated T4 cell counter as previously described with
minor modifications (Sun et al., 2015). Briefly, cells were harvested and plated in a 6-well plate
at a density of 2 x 104 cells/well (2 technical replicates per treatment/genotype/time point). 4
hours post plating, cells were harvested by trypsinization and counted in the presence of trypan
blue. This time point was designated as the starting point (T0) of the time course. Cells were
then harvested and counted every 24 hours for a total of 4 days (24, 48, 72 and 96 hours). This
experiment was repeated three times.

3.3.5 Clonogenic cell frequency assay: Extreme Limiting Dilution Assays (ELDA analysis)
Clonogenic capacity of male and female GBM cells (Nf-/-;DNp53 astrocytes) treated with
DMSO (0.05%), JQ1 (500 nM), or RVX-208 (5µM) for 24 hours or shRNAs was assayed by
the Extreme Limiting Dilution Assay (ELDA). The frequency of clonogenic stem cells was
evaluated by the cells’ ability to form tumor-sphere in low-adherent conditions as previously
reported (Sun et al., 2015). Briefly, cells were harvested into a single cell suspension and plated
in neurosphere media containing EGF and FGF on 96-well ultra-low attachment plates in a
serial dilution ranging from 3000 cells/well to 1 cell/well (3000, 600, 120, 24, 5 and 1 cells;
n=14/cell density). Sphere formation was measured 7 days after plating. Clonogenic stem-like
cell frequency was analyzed using the Extreme Limiting Dilution Analysis
(http://bioinf.wehi.edu.au/software/elda/).

3.3.6 In vivo tumorigenesis: flank implantation
Flank tumors were generated by implanting GBM astrocytes at various cell numbers
subcutaneously into left and right side flanks (top and bottom). These cells were treated with
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EGF for one week (50ng/ml) followed with a 0.05% DMSO or 500 nM JQ1 treatment for 24
hours. 1 million, 500,000, 100,000 or 5000 cells were then harvested and resuspended in 100 µl
of 1:1 media to matrigel (BD Biosciences) and injected into the four flanks of mice. Mice were
monitored weekly and tumor growth was monitored blindly for 7-8 weeks with thrice weekly
micrometer measurements in 3 dimensions. Animals were used in accordance with an animal
studies protocol (no. 20150177) approved by the Animal Studies Committee of the Washington
University School of Medicine per the recommendations of the Guide for the Care and Use of
Laboratory Animals (NIH).

3.3.7 shRNAs lentiviral infection and knockdown of Brd2 and Brd4
Brd2 and Brd4 knockdown lines were generated by infecting male and female GBM cells
(Nf-/-;DNp53 astrocytes) with lentiviral shRNAs against Brd2 or Brd4. We used a pool of 5
shRNAs for Brd4 as well as Brd2. Both Brd2 and Brd4 Knockdown lines were selected with
puromycin (2.5 µg/ml) in media for 1-2 weeks and the survivors were expanded for
downstream target knockout analysis.

3.3.7 Quantitative Real-Time PCR
Total RNA was isolated using Trizol RNA extraction method (Invitrogen, CA) from male
and female GBM cells (Nf-/-;DNp53 astrocytes) infected with shRNAs lentivirus against Brd2
or Brd4. cDNA was generated using the QuantiTect Reverse Transcription Kit (Qiagen).
Quantitative RT-PCR was performed using gene-specific primers and iTaq SYBR Green PCR
master mix (Biorad, CA). Data was analyzed by standard ΔCq method (2-ΔΔCq) where ΔCq is
the difference between the gene of interest and GAPDH control Cq value.
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3.3.7 Statistical analysis
All experiments in this study were carried out at least three times. ANOVA and two-tailed
Student’s t-test were used to compare the differences in all functional measurements between
JQ1, RVX-208 and control group (DMSO), and a p-value < 0.05 was considered statistically
significant.
To test if upregulated genes in male cells compared to female cells and vice versa are
significantly enriched for H3K27ac binding, the normalized H3K27ac signal intensities (reads)
from 1kb upstream of the gene start site to 1kb downstream of the end of the gene were used for
the correlation analysis. A paired Mann-Whitney-Wilcoxon test was used to compare
normalized H3K27ac signal intensities between male and females cells and a p-value less than
0.01 was considered statistically significant.
To investigate if Brd4-proximal genes are significantly downregulated upon JQ1
treatment compared to Brd4-distal genes, we first defined Brd4 proximal genes as the closest
genes to Brd4 binding sites and Brd4 distal genes as genes located near sites that are not
enriched for Brd4 binding sites(353 male genes and 292 female genes). The expression profiles
before and after JQ1 treatment of Brd4 proximal and distal genes were used for a MannWhitney-Wilcoxon test for male and female respectively and a p-value less than 0.01 was
considered statistically significant.

3.3.7 TCGA human GBM data analysis
Level 3 RNA-seq gene expression data for TCGA GBM samples were obtained from the
Broad GDAC Firehose data portal. Clinicopathologic data for the GBM samples were obtained
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from the cBioPortal for cancer genomics. Only tumor samples that represented primary tumors
were used and recurrent tumor samples were excluded from the analysis. In total, gene
expression and clinicopathologic data of 98 males and 53 females were used in this analysis.
To identify sex differences in overall survival (OS) outcomes for Brd4 in GBM patients,
male and female patients were stratified into different expression groups and differences in
survival outcomes among groups were then assessed 116. The Brd4 gene expression value was
first transformed into a z-score that was specific to the sex of the patient, and the patients were
grouped into high expression group (Z > 1.0) and low expression group (Z < -1.0). The patient
groups of each sex were associated with survival endpoints by the Kaplan-Meier method, and
log-rank test was used to compare survival difference among groups. High expression and low
expression groups were analyzed separately.

3.3.7 Data availability
All Illumina sequencing reads and processed file have been deposited in the Short Read
Archive/GEO database (http://www.ncbi.nlm.nih.gov/geo/).
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Chapter 4
High-throughput functional identification of
enhancers using a CRE recombinasemediated reporter assay
4.1 Abstract
Enhancers are DNA sequences that regulate the timing, tissue-specificity, and level of gene
expression. Developmental enhancers are critical determinants of normal organismal
development and cellular differentiation 134, and changes in their functions likely underlie
biological processes ranging from cell fate decisions to disease susceptibility 37, 46, 135. Despite
their importance, genome-wide discovery of developmental enhancers remained challenging 136.
Here, we developed a CRE recombinase-mediated method for the functional identification of
active enhancers at different time periods of development, named as Developmental Enhancer
Sequencing (DevEn-seq). Genomic integration of a single copy enhancer and a CRE reporter
assay are coupled with high-throughput sequencing to enable parallel screening and tracking of
large numbers of enhancer candidates. We demonstrated that DevEn-seq is able to detect
enhancers more efficiently than regular reporter methods and trace enhancer activities without
being disturbed by the gene silencing effect caused by lentiviral sequences. By functionally
interrogating >500 kilobases (kb) of mouse sequence in mouse embryonic stem cells for
enhancer activity, we identified 38 enhancers at pluripotency loci with a positive predictive value
of 80%. With an in vitro neural differentiation protocol, we identified two neural progenitor-
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specific enhancers around HB9 and Olig2 genes. DevEn-seq is a high throughput method for
functional identification and tracking of enhancer activities throughout cellular differentiation.

4.2 Introduction
The ability to create distinct cell types is fundamental for the development of multicellular
organisms. Since all cells in an organism contain the same genes, cellular diversity is achieved
through the distinct regulatory DNA elements or enhancers throughout the genome that control
the spatial and temporal expression patterns of specific sets of genes, leading to a cell’s
specialized role134. Developmental enhancers are frequently tissue-specific or cell type-specific3537

and provide the genomic landscapes required for the binding of key TFs that drive cell-specific

gene expression programs135. Despite their importance, developmental enhancer discovery has
remained challenging and their regulatory role has not been characterized in detail because
understanding these regulatory mechanisms requires the global functional identification of
differentially active enhancers in development137.
Genome-wide approaches for enhancer identification are mostly based on the indirect
assessment of enhancer-associated markers such as histone modifications and binding of
transcription factor p300 by ChIP-seq or DNase digestion followed by sequencing (DNaseseq)138. Currently, there are two general strategies for the genome-wide prediction of enhancers:
1) Deep sequencing of DNase I-hypersensitive sites (DNaseI-HS seq) 139 or formaldehydeassisted isolation of regulatory elements sequencing 140 (FAIRE-seq), which allow for the
mapping of open chromatin; 2) Chromatin immunoprecipitation followed by deep sequencing 141
(ChIP-seq) enables the detection of regulatory (e.g., TF or cofactor) binding sites and enhancer
associated histone modifications [e.g., histone 3 (H3) Lys4 monomethylation (H3K4me1) or H3
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Lys27 acetylation (H3K27ac)]. These methods have provided an expanded view of chromatin
landscapes as well as insights into the relationship between active enhancers and the dynamics of
chromatin modification and remodeling. However, one limitation of these approaches is that they
are associated with false positive and false negative errors because they lack a direct functional
or quantitative readout of enhancer activity and putative enhancers predicted this way requires
further functional validation by reporter assays142, 143. In addition, the genomic loci defined by
these marks typically span several kilobases (kb) and are generally too broad to define the
specific DNA sequences mediating enhancer function.
Functional approaches for identifying active enhancers rely on functional assays of
individually transfected reporter plasmids harboring putative regulatory regions144, but most of
these assays do not scale to the millions of tests required for global identification of enhancers.
Recently, several groups have developed massively parallel reporter assays (MPRAs) that permit
the simultaneous analysis of hundreds of thousands of reporter plasmids and, thereby, a
functional assessment of the transcriptional-activation properties of large numbers of genomic
regions 142, 143, 145. However, MPRAs have primarily been used as a way to dissect the functional
components of previously identified transcriptional regulatory DNA elements rather than as a
tool for the discovery or screening of enhancer in mammalian cells. Even with these advances,
the enormous size and complexity of mammalian genomes, and the concomitant number of
required reporter plasmids, remain among the primary challenges to using functional approaches
for the de novo discovery of enhancers.
More recently, two high-throughput functional approaches for enhancer identification have
been developed: self-transcribing active regulatory region sequencing (STARR-seq) and
enhancer-FACS-seq (eFS) 146, 147. In STARR-seq, sheared DNA fragments are inserted within a
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noncoding portion of the reporter plasmid transcription unit, and enhancer activity is detected in
transfected cells by the ability to self-transcribe, permitting identification of 5,499 elements 146.
eFS instead is a highly parallel functional screen for identifying developmentally relevant,
mesodermal-specific enhancers within developing Drosophila embryos 147. Although both
STARR-seq and eFS are elegant systems for enhancer discovery in Drosophila, their successful
application to the analysis of large mammalian genomes is uncertain. Either human or mouse
genome is roughly 23 times larger than that of D. melanogaster, suggesting that initial STARRseq libraries would require over 200 million unique plasmids, and a preliminary study using
STARR-seq analysis of human DNAs identified only six enhancers from a plasmid library
consisting of 1.3-million unique genomic regions derived from 1 Mb of human DNA. In
addition, STARR-seq relies on transient delivery of enhancer-reporter plasmids, limiting the use
of these methods to a small number of easily transfected cell types. Furthermore, the relevance of
STARR-seq identified enhancers to endogenous gene expression is less clear, as many
correspond to closed chromatin regions. eFS focuses on potentially relevant portions of the
genome, but an eFS-like approach using transgenic mouse embryos for screening genomic
segments would be prohibitively expensive for most researchers.
Here, we developed a high-throughput functional method to identify enhancers and track
their activity changes at different stages of cellular development. We first utilized a CREreporter embryonic stem cell (ESC) line that has a single copy transgene integrated at the Rosa26
locus of the mouse genome148. The transgene contains a strong and ubiquitously expressed CAG
promoter followed by a loxP-flanked (‘floxed’) stop cassette-controlled red fluorescent gene
(RFP) (Fig. 4.1). We position the enhancer fragments upstream of a CRE recombinase gene in a
lentiviral transfer vector to produce lentivirus, which permits the individual assessment of
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enhancer activity of millions of fragments at the lentiviral integrated genomic loci. If the
integrated lentiviral transgene harbors an active enhancer that is able to drive the CRE
expression, CRE will flip out the stop cassette and in turn activate the expression of RFP within
the CRE-reporter ESC (Fig. 4.2). The ubiquitously expressed RFP at Rosa26 locus then becomes
a permanent marker for that enhancer element activity in the lentiviral transgene and survives the
cellular division and differentiation. After in vitro differentiation of the transduced CRE-reporter
ESCs, the RFP positive and negative cells along each cell lineage are collected by fluorescenceactivated cell sorting (FACS). The enhancer elements within the RFP positive cells and the
corresponding non-enhancer elements in RFP negative cells are recovered by PCR and
sequenced by Illumina HiSeq, which produces a genome-wide map of lineage-specific enhancers
in development.
To control the tracing time window, we created a chimeric protein consisting of CRE fused
to the ligand binding domain of the estrogen receptor (ERT2, Fig. 4.2). The fusion protein is
constitutively expressed but sequestered outside of the nucleus by binding to the cytoplasmanchored protein HSP90. The treatment of ER antagonists (4-hydroxy tamoxifen; 4OHT) causes
the fusion protein to translocate into the nucleus and recombine the loxP sites16. To obtain a high
temporal resolution of the enhancer activity along development, we used a degradation domain
of ERT2 that confers short protein half-life and attached it to both N and C terminus of the CRE
(dERT2:CRE:dERT2). The lentiviral transgenes carrying candidate enhancers corresponding to
each time window were recovered and sequenced.
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Figure 4.1 Schematic diagram of the gene targeting strategy to generate CRE-reporter cell
line. The CRE-reporter cassette was inserted into the Rosa26 locus, in the intron between
endogenous exons 1 and 2.

Figure 4.2 Overview of CRE-mediated enhancer screen. DNA test fragments containing
putative enhancers are linked to an inducible CRE and then are integrated into genome by
lentiviruses. After drug selection, each cell in the library contains no more than one candidate
fragment. If the enhancer is active in a cell, CRE recombinase will be expressed and remove a
stop codon in an RFP reporter and permanently generate red cells in itself and its progeny. RFP-
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expressing cells are isolated by flow cytometry, and presumptive enhancer sequences from these
cells are amplified and sequenced. ES cell libraries can be differentiated in vitro before sorting.

4.3 Results
4.3.1 Active enhancers can be efficiently detected using a CRE reporter assay.
Current methods for functional identification of enhancers use a basal vector in which a
minimal promoter is positioned in front of a reporter. The enhancer fragments are cloned
upstream of this minimal promoter to test their transcriptional activity. To develop our CREmediated enhancer identification methodology, we first sought to engineer a minimal promoter
from which the basal expression of the CRE protein in the absence of an enhancer should be
below the level of recombination required to trigger reporter (RFP) expression. A total of five
minimal promoters that have been successfully applied for fluorescence or LacZ-based enhancer
detection were evalutated: heat shock protein 68 (HSP68)149, β-globin (HBB)150, oncogene c-fos
(cFOS)151, fibroblast growth factor 4 (FGF4)152, and super core promoter (SCP)146. These
minimal promoters were cloned upstream of CRE with and without CMV enhancer (CMVE).
The CRE-reporter ESCs were transfected with these constructs and the percentage of RFP
positive cells were measured by FACS. As shown in Fig 4.1, the basal transcriptional activity of
all five minimal promoters is different: SCP, HBB, and FGF4 are all below 0.5% while cFOS
and HSP68 are 2% and 5%, respectively. The addition of CMV enhancer increases the RFP
positive cells significantly for all five minimal promoters and the percentage ranges from 30% to
45% (p>0.05). For an enhancer identification assay, a lower basal activity and higher signal are
optimal. Therefore, we calculated the induction fold change as the ratio of RFP positive cells
observed in the CMV enhancer-driven construct to those in the corresponding non-enhancer73

driven construct and chose FGF4 minimal promoter for the CRE-mediated assay because its ratio
is the highest among all five.

Figure 4.3 Optimization of minimal promoters for the CRE-mediated enhancer
identification. Five minimal promoters were cloned upstream of CRE gene with (red) and
without (grey) a CMV enhancer (CMVE).

4.3.2 CRE activity can be induced by a degradation domain of ERT2
To assess the enhancer activity in a specific time window during a differentiation process,
we created a chemically inducible CRE by fusion to a regular or degradable ERT2 (dERT2)
domain. The ERT2 fusion protein is sequestered outside of the nucleus by binding to the
cytoplasm-anchored protein HSP90 and is released from the inactive complex in the presence of
4-OHT153. To have an optimal inducible CRE, three CRE variants were created. Single and
double copies of the ERT2 domain were fused to CRE (ERT2:CRE and ERT2:CRE:ERT2), and
double copies of degradation domain of ERT2 (dERT2) were fused to CRE
(dERT2:CRE:dERT2). These CRE variants were evaluated on two parameters: 1) the enzymatic
activity of the fusion protein relative to that of the unfused one and 2) the fold induction between
induced and non-induced states. As shown in Fig 4.2, three CRE variants have similar activities
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to unfused CRE (p>0.05), suggesting that the attached ERT2 domain does not significantly affect
the CRE activity, regardless of the N and C-terminal fusions. In terms of inducibility,
ERT2:CRE:ERT2 and dERT2:CRE:dERT2 fusion proteins showed similar induction fold and a
much higher than the CRE:ERT2 variant (p<0.05), indicating that two copies of the ERT2
domains increase the inducibility significantly than single copy. Taken together,
ERT2:CRE:ERT2 and dERT2:CRE:dERT2 fusion proteins both have good enzymatic activity
and inducibility and are therefore optimal candidates for CRE-mediated reporter assay.
We next evaluated the half-life of the fusion protein dERT2:CRE:dERT2 and
ERT2:CRE:ERT2 because the rate at which the inducible CRE degrades defines the temporal
resolution of the CRE-mediated reporter assay. To have a high temporal resolution, the inducible
CRE synthesized earlier should degrade quickly to an extent that CRE “carryovers” would not
interfere with newly synthesized CRE upon induction. To compare the half-life of the fusion
protein of ERT2:CRE:ERT2 and dERT2:CRE:dERT2, mRNAs from both CRE variants were
synthesized by in vitro transcription and transfected into the CRE reporter ESCs treated with cell
cycle inhibitor (abl kinase inhibitor). Chemical inducer 4OHT was added into the culture
medium to activate the CRE-mediated system at different time points ranging from 0h to 72h
posttransfection and the percentage of RFP positive cells was measured. As shown in Fig 4.2 B,
the percentage of RFP positive cells transfected with dERT2:CRE:dERT2 mRNA drops
significantly compared to those transfected with ERT2:CRE:ERT2 mRNA, suggesting that the
half-life of dERT2:CRE:dERT2 is shorter than ERT2:CRE:ERT2. This result is expected
considering that degradation domain is unstable154 and demonstrates that dERT2:CRE:dERT2 is
able to offer a higher temporal resolution for the CRE induction system.
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Figure 4.4 Development of an inducible CRE system a degradation domain of ERT2. (A)
Evaluation of the inducible CRE systems made from different CRE-ERT2 fusion variants. (B)
Estimation of the degradation time of inducible CRE variants.

4.3.3 CRE-mediated enhancer identification has a higher sensitivity than a regular
fluorescence-based assay
We next investigated whether enhancers placed upstream of the FGF4 minimal promoter
and CRE variants could be efficiently identified compared to a regular reporter assay which
places enhancer fragments upstream of fluorescent protein. We selected three active enhancers:
SP1 enhancer (SP1E), CMV enhancer (CMVE), SV40 enhancer (SV40E) and one non-enhancer
(NE) marked by intensely dense chromatin in a gene desert region. CRE reporter ESCs were
transiently transfected with the enhancer-driven and non-enhancer-driven constructs and the
percentage of RFP positive cells were measured. As shown in Fig 4.3, non-enhancers showed no
signal using either method, while active enhancers showed a significantly higher percentage of
positive cells in all variants of CRE-mediated enhancer identification than a regular RFP based
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assay (p<0.05), indicating that CRE-mediated enhancer identification has a higher sensitivity
than a regular fluorescent-based assay.

Figure 4.5 Comparison of the regular fluorescent based enhancer identification with CREmediated enhancer assay. One non-enhancer sequence (NE) and three enhancer sequences
(SP1E, CMVE and SV40E) were cloned upstream of RFP reporter gene to measure their
transcriptional activity. In the meanwhile, these sequences were positioned upstream of three
CRE variants individually to tested enhancer activity. The readout is the percentage RFP positive
cells for both methods.

4.3.4 Neural differentiation of CRE-reporter ESCs generates motoneurons, astrocytes, and
oligodendrocytes
To develop an in vitro cell culture differentiation system, we adapted a protocol from the
Sakiyama-Elbert lab to differentiate the ESCs to neural lineages: motorneurons,
oligodendrocytes, and astrocytes155, 156. This in vitro cell differentiation protocol consists of
culturing whole embryoid body (EB) aggregates on gelatinized plates in DFK5 media containing
retinoic acid (RA) and sonic hedgehog agonist (SAG), dissociating induced EBs (day 6), and
77

plating the single cells on poly-ornithine plates for 7-10 days (Fig 4.4 A). The fully differentiated
cells were stained with cell-type specific antibodies against beta-tubulin class II to mark neurons,
Olig2 to mark oligodendrocytes, or GFAP to mark astrocytes. We observed all three neural
lineages in roughly in equal amounts (Fig4.4 B), suggesting we are able to obtain an unbiased
representation for each cell type in a single differentiated culture.

Figure 4.6 Neural differentiation of CRE-reporter ESCs. (A) Timeline of the neural
differentiation protocol. (B) Antibody staining of neurons, astrocytes, and oligodendrocytes.
Differentiated ESCs were stained with antibodies against beta-tubulin class II to mark neurons
(a), GFAP to mark astrocytes (b), or Olig2 to mark oligodendrocytes (c). Nuclei were stained
with DAPI. Phase contrast and fluorescent images were positioned at the top and bottom,
respectively.
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4.3.5 Enhancer activity can be tracked during neural differentiation of ESCs
To test if CRE-mediated enhancer identification can track a given enhancer’s activity
through neural development, we selected three genes that are transcriptionally active at three
different stages of neural differentiation: Nanog, Nestin, and ChAT(choline acetyltransferase),
corresponding to the ESC, embryoid body (EB), and mature neuron stages, respectively90, 157-159.
The enhancer element of each candidate gene was previously identified160-162. We then PCRamplified these enhancers and individually positioned them upstream of dERT2:CRE:dERT2 in
a basal lentiviral screen vector. We also included EF1 promoter and non-enhancer sequence as
positive and negative controls. CRE reporter ESCs were transduced with these lentiviruses
individually and selected under blasticidin S deaminase (BSD) for 5 days to obtain polyclonal
cell populations for each transduction. The polyclonal cell populations were further induced with
4-OHT at three developmental stages: ESC, EB, and mature neuron respectively as shown in Fig
4.5. The cells transduced with positive and negative enhancer sequences showed consistently
high and low percentages of RFP positive cells in all three developmental stages, respectively,
indicating validity of the assay (Fig 4.5). At the ESC stage, sequence from Nanog showed a
significantly higher RFP positive percentage than any other enhancers (p<0.05). At EB and
mature neuron stages, cells with Nestin and CHAT enhancer sequences demonstrated the highest
percentages of RFP positive cells, respectively (p<0.05). These results are consistent with
previous findings160-162 and suggest that enhancers active at different stages or time periods can
be efficiently detected by the CRE-mediated assay.
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Figure 4.7 Enhancer strength assayed at three stages of the neural differentiation. Positive,
negative and three enhancer sequences (Nanog, Nestin, and ChAT) were tested by CREmediated enhancer assay at the three stages of neural differentiation: (A) ESC, (B) EB and (C)
MN. The RFP positive cells were measured at each stage. “**” indicates a p value less than 0.01.
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4.3.6 DevEn-Seq accurately identifies mouse ES cell enhancers
To identify mouse ESC enhancers, we constructed an enhancer library by shearing a pool
of 6 bacterial artificial chromosomes (BACs) containing genes of interest into ~500bp fragments
(Fig 4.2). The BACs contain the pluripotency genes Sox2, Oct4, and Nanog that all have a high
density of sites marked with H3K27ac or the histone acetyltransferase p300 at the ESC stage,
both strong predictors of enhancer activity160. The BACs also cover HB9 and Olig2 genes. The
HB9 gene is active at the neural progenitor cell (NPC) stage and promotes motoneuron cell155,
163

. The Olig2 gene is expressed in motoneuron progenitor cells in two waves. The first wave of

expression acts to produce motoneurons, the second, oligodendrocytes164-166. We cloned the
sheared BAC fragments upstream of dERT2:CRE:dERT2 under the control of FGF4 minimal
promoter in a basal lentiviral vector and produced the lentiviruses from the lentiviral plasmid
library. CRE reporter ESCs were transduced with the lentiviral library and selected under BDS
for 3 days to remove cells that do not have lentiviral integration, while maintaining leukemia
inhibitory factor (LIF) in the medium to maintain pluripotency. To identify the active enhancers
present at the ESC stage, the chemical inducer 4OHT was applied immediately after BSD
selection to activate the CRE-mediated enhancer detection system and RFP positive and negative
cells were sorted. To calibrate the sorting process, we used cell populations transduced with
lentiviruses that have non-enhancer and EF1 promoter driving inducible CRE as negative and
positive controls, respectively. Fig. 4.6 showed that cells from the negative control showed
universally low reporter expression, in contrast to the positive control, in which the majority of
cells showed strong RFP expression. The BAC enhancer library from randomly sheared BACs
contained a small population of cells with robust reporter expression and a large population with
negligible reporter expression, which is expected considering that any given genomic locus is
81

likely to harbor only a few enhancers active in any given cell type137. We collected the RFP
positive cells which are expected to contain an enhancer activating the CRE-reporter system and
RFP negative cells that are expected to have a transcriptionally inactive non-enhancer. We then
amplified the enhancer candidate sequences in these harvested cells by PCR using universal
primers that recognize the sequences flanking the enhancer site, sequenced enhancer amplicons
using high-throughput sequencing technology, and mapped the reads to the BAC reference
sequence. To check the coverage or distribution of the enhancer fragments, we also amplified
and sequenced fragments present in the plasmid library and mapped it back to the BAC
sequences. We found that the enhancer fragments from the plasmid library cover ~90% of all
BAC sequences and the locus shown specifically in Fig. 4.7 showed 100% coverage of the
selected region. Functionally active enhancers (Fig. 4.7 row4) were defined as those sequences
that showed a significant enrichment in the fluorescent cell population (Fig. 4.7 row2) relative to
the negative population (Fig. 4.7 row3). For DNA regions around pluripotent genes, a total of 48
enhancer regions were identified (Fig. 4.8 A).

Figure 4.8 Graphs of FACS for cell soring. The plots show fluorescent intensity of RFP
reporter gene for negative control (no RFP expression) and positive control (strong RFP

82

expression), and ES cells transduced by lentiviral library. Points represent unique cells. Red dots
in P4 delineate the gate for cells considered positive for reporter gene expression.

input
negative
positive
positive2
negative

Figure 4.7 Genome browser view of enhancer peaks. Sequencing reads from input plasmid
library, RFP negative cells, RFP positive cells were uniquely mapped. To identify enhancer
peaks, the ratio of reads from positive over negative cells is calculated.

To confirm the accuracy of the method, we examined the enhancer activities of 20
candidate enhancer sites out of a total of 32 identified by DevEn-seq and an additional 19 sites
with no enhancer activity (referred to as ‘non-enhancer’). Each site was amplified from the
genome and then cloned upstream of unfused CRE under control of the FGF4 minimal promoter
for validation. The CRE-reporter ESCs were transfected with these constructs and the percentage
of RFP positive cells was measured. We observed robust enhancer activity for 16 of the 20
(80%) DevEn-seq predicted enhancers (Fig. 4.8 B). This is in contrast to the sequences predicted
to have no enhancer activity by DevEn-seq, 16 of 19 (84%) had negligible reporter expression.
Collectively, the enhancers predicted by DevEn-seq drove significantly higher reporter
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expression than those that were predicted by DevEn-seq to have no enhancer activity (p<0.05).
The high validation rate in these complementary assays demonstrates the accuracy of
identification of enhancers by DevEn-seq. To further estimate the positive predictive value, we
overlapped the active enhancer peak regions with evidence of DNaseI hyper-sensitivity (HS) and
histone modifications H3K27ac. Almost ~85% of the active enhancer peaks harbored at least one
of these two enhancer markers. Taken together, these results showed that DevEn-seq is able to
identify active enhancers at the ES cell stage with a high positive predictive value of ~85%.
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Figure 4.9 Mouse ESC enhancers identified by DevEn-Seq. (A) Mouse ESC enhancers
(purple peaks) from pluripotent genes Sox2, Nanog and Oct4 loci. Enhancer peak represents
(normalized RFP positive read depth)2 /normalized RFP negative read depth. Peak signals >1
represent sequences enriched in the RFP positive population relative to the negative ones. For
simplicity, only DevEn-seq signal is shown. (B) Validation of mouse ESC enhancers and nonenhancers identified by DevEn-seq. Candidate enhancer and non-enhancer regions were marked
by red and blue rectangles in A. A total of 20 enhancers (red dots in B and red rectangles in A)
and 19 non-enhancers (blue dots and blue rectangles in A) regions were tested by CRE-mediated
reporter assay individually. The dash line indicates the cutoff for positive and negative results.
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Validated and non-validated sequences were marked by solid and dash rectangles respectively in
(A).

4.3.7 DevEn-Seq can identify developmental enhancers during neural differentiation
To identify enhancers that are active at neural progenitor cell (NPC) stage during neural
differentiation, we used the polyclonal ESCs obtained from previous experiment and initiated the
CRE-mediated enhancer assay by 4OHT when EBs were induced to generate motoneurons from
Day4 to Day6 (Fig4.9 A NPC-MN). As for control and comparison, we included two additional
time windows for induction and harvest: 1) induction from ESC Day -1 to ESC Day -3 and
harvest at ESC Day -3 (Fig 4.9 A ES-ES) and 2) induction from ESC Day -1 to MN Day 10 and
harvest at MN Day 10 (Fig 4.9 A ES-MN). For each experiments, both RFP positive and
negative cells were collected by FACS for PCR amplification and sequencing. The sequencing
reads were mapped back to BAC reference and peaks for each condition were called. To identify
NPC specific enhancers, we compared peaks in condition of NPC-MN to the other two
conditions and found that a cluster of peaks around HB9 gene were enriched for the read depths
(Fig. 4.9 B, red rectangle), suggesting that this enhancer element may play a role in specifying
NPC fate. Previous studies155, 163 on HB9 gene indicate that this NPC specific enhancer region
matches the highly conserved enhancers of HB9 and is used for purifying NPC-derived
motoneurons from a mixture of other neural cell types including oligodendrocytes and
astrocytes. In addition, we found two peaks enriched around Olig2 gene (Fig. 4.9 C, red
rectangle), which are consistent with what previously found to be NPC-specific regulatory
sequences167, 168. These results suggest that DevEn-seq can identify cell type specific enhancers
during neural differentiation throughout development.
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Figure 4.10 NPC-specific enhancers identified by DevEn-seq. (A) Timeline of neural
differentiation. Red line indicates the induction time window and the black arrow denotes the
starting and ending points for each experiment. (B and C) Genome browser view of the enhancer
peaks from three conditions. The peaks in the red rectangle at condition of NPC-MN indicates
the NPC specific enhancers around HB9 gene (B) and Olig2 gene (C).

4.4 Discussion
Regular methods for functional identification of enhancers place enhancer fragments
upstream of a minimal promoter and a reporter to test its transcriptional activity. One major
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concern is that the integrated lentiviral sequences become methylated and repressed during
differentiation, regardless of the sequences driving the reporter, causing the initial positive
signals to disappear from the differentiated cells 152. DevEn-seq positions the enhancer fragments
upstream of a CRE gene that initiates the cascade reactions to activate the ‘real’ reporter. By
adopting CRE/loxP system and a CRE-reporter cell line, the reporter gene is not in the lentiviral
transgene but was transferred to the Rosa26 locus, a ubiquitously expressed locus that survives
the methylation-driven gene silencing in development 148.
DevEn-seq also has a higher sensitivity than regular methods that use fluorescent protein as
reporter because the amount of CRE recombinase required to activate the CRE/loxP system is
lower than that of fluorescent reporter protein to be detected by FACS. In addition, once the
CRE/loxP system is activated, the reporter of DevEn-seq is under a strong CAG promoter at
Rosa26 locus, which can provide a strong and ubiquitous expression of the reporter gene.
By functionally interrogating >500 kilobases (kb) of mouse sequence in mouse embryonic
stem cells for enhancer activity, we identified 38 enhancers at pluripotency loci with a positive
predictive value of 80%. With an in vitro neural differentiation protocol, we identified two neural
progenitor-specific enhancers around the HB9 and Olig2 genes. This demonstrated that DevEnseq can be used to trace enhancer activity without being disturbed by the gene silencing effect
caused by lentiviral sequences and is limited only by currently available stem cell differentiation
methods.
The need for high-throughput assays to directly interrogate enhancer activity has led to the
recent development of multiplex methods to functionally assess genetic regulatory elements 142,
143, 146, 147, 169-171

. However, most of these methods rely on transient delivery of enhancer-reporter

plasmids, limiting the use of these methods to a small number of easily transfected cell types.
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Furthermore, many enhancers have been shown to have negligible or different activity when
tested in transient assays but robust activity when integrated into the genome 172-174. This
suggests that transient delivery of enhancer-reporter constructs may not recapitulate the native
chromatin environment found in chromosomes, which may be necessary for proper gene
regulation. DevEn-seq improves substantially on these previous methods by assessing
mammalian enhancer activity in a genomic context and in a potentially much wider variety of
cell types.
The number of putative enhancers assessed in a single DevEn-seq experiment is currently
limited by the transduction efficiency in mouse ES cells. For the experiments described,
lentiviral genome integration occurred in approximately one in 105 mouse ES cells at an MOI of
0.3. Due to the enormous size of mammalian genomes, performing unbiased enhancer discovery
across an entire genome may therefore prove too experimentally arduous for DevEn-seq. New
technologies to improve stem cell permissiveness to HIV-derived lentiviral vectors and relieve
host lentiviral restriction blocks may improve this integration efficiency and thereby increase the
throughput of this approach175. Alternatively, limiting the library or search space to the
accessible cellular chromatin that are most relevant for endogenous transcriptional regulation
could potentially allow for a more efficient enhancer screening by DevEn-seq. It was previously
shown that the efficiency of identifying biologically relevant transcriptional regulatory elements
can be dramatically increased by focusing on DNA isolated from nucleosome-free regions
(NFRs) 176, 177 (i.e., genomic regions in which nucleosomes are relatively depleted and/or highly
destabilized). Notably, NFRs represent only 2% of chromatin. Thus, by focusing functional
analysis on NFR-derived DNA reduces the search space to the most relevant portions of the
genome and eliminates the need for a whole genome screen.
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As mounting evidence for enhancer’s contributions to development and human disease, the
identification of enhancer elements in different cell types and under different biological
conditions is currently of high priority in biomedical research. DevEn-seq will help to overcome
the limitations currently curbing the ability to functionally identify or validate large numbers of
putative enhancers directly in many disease-relevant cell types throughout development. For
example, DevEn-seq has the potential to decrease the need for transgenic mice to test enhancers
active in specific cell types. Moreover, future development of DevEn-seq could allow for the
more comprehensive study of the roles of enhancers in human disease and ultimately guide the
reprogramming of embryonic or induced pluripotent stem cells to produce specific cell types for
personalized transplants, such as pancreatic beta cells to treat diabetes.

4.5 Method
4.5.1 Constructing plasmid libraries
BACs that contain the genes of interests were ordered from the BACPAC Resource Center
at Children's Hospital Oakland Research Institute. BAC DNA was isolated by MACHEREYNAGEL NucleoBond® Xtra BAC kit and sheared with a Covaris S220/E220 Focusedultrasonicator using parameters of generating ∼1kb long DNA fragments. The fragmented DNA
were further size-selected using 1% agarose gel. Illumina Multiplexing Adapters were ligated to
1µg size-selected DNA fragments using Accel-NGS® 2S Plus DNA Library Kit (Swift
Bioscience) following manufacturer’s instructions. The screening vector was linearized by a 16hour digestion with MreI (Thermo Fisher Scientific) and AscI (NEB), followed by agarose gel
electrophoresis and QIAquick gel extraction.
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The adapter-ligated fragments were recombined to the linearized screening vector by InFusion HD kit (Clontech) in a total of 2 10ul reactions. The In-Fusion HD reactions were pooled,
ethanol precipitated and eluted in 20µl EB [10mM Tris-HCL, pH 8]. Two aliquots (40 µl each)
of MegaX DH10B Electrocompetent Bacteria (Invitrogen) were transformed with 10µl eluted
DNA each, according to the manufacturer’s protocol. After one hour recovery at 37 °C, two
transformation reactions were pooled and grown on six LB-AMP 245mm x 245mm plates
(Corning). The plasmid libraries were extracted using Plasmid Maxi kit (Qiagen).

4.5.2 Preparation of lentiviral libraries
The lentiviral libraries were prepared by the Hope Center viral core at Washington
University School of Medicine as previously described [Production of Lentiviral Vectors for
Transducing Cells from the Central Nervous System]. Lentiviral titres will be determined in
triplicate by transducing 1 × 105 HT1080 cells with serial dilutions of concentrated viruses
(1:100 to 1:10000). After 72h incubation, the genomic DNAs of each transduced samples will be
extracted. The six point standard curves from 106 to 102 copies will be generated by serial
dilution of lentiviral gene and human gene (Albumin) fragments respectively. The number of
lentiviral gene copies will be determined by quantitative PCR (qPCR) with primers recognizing
the lentiviral LTRs while number of mouse genomes will be determined using primers
recognizing a unique human gene (Albumin). Titres will be determined according to the
following formula (Fig 4.11) and expressed as transducing units/mL (TU/mL). The titres will be
used to balance the differences of infectious efficiency for each batch of viruses, ensuring the
consistency of the experiment.
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Figure 4.11 The formula for calculating the lentiviral titre.

4.5.3 Transduction of lentiviral libraries and drug administration
Mouse ESCs were transduced at a MOI of 0.2 to ensure that a majority of cells (~90%
according to Poisson distribution) was transduced with a single-copy viral integration. To
increase the likelihood that any given BAC-lentiviral fragments would be represented, the
number of cells transduced was equivalent to more than 30 times each library’s complexity.
Considering the MOI of 0.2, xxx × 106 ESCs were plated in complete ESC medium plus LIF in
feeder-free conditions on a 10-cm gelatin-coated dish 1 d before transduction. The cells were
then transduced overnight in 10 ml of complete ESC medium plus 10 µg/ml Polybrene. The
following day, the medium was replaced with fresh ESC medium plus LIF. Blasticidin selection
was initiated 4 d post transduction in ESC medium/LIF containing 5 µg/ml Blasticidin S. Cells
were selected for Blasticidin resistance for 5 d, with medium changed daily. To activate the cremediated enhancer identification, cells were treated with 1 µM 4-hydroxy tamoxifen (4OHT,
Sigma) and maintained for at least one day for full activation.

4.5.4 Neural differentiation
Mouse ESCs were differentiated into neurons, oligodendrocytes and astrocytes using a
retinoic acid (RA) and smoothened agonist (SAG) induction protocol as described 93. Briefly,
ESCs were cultured in suspension on low attachment plates (Corning) in modified DFK5 media
consisting of DMEM/F12 base media (Gibco) containing 5% knockout serum replacement, 1 ×
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insulin transferrin selenium, 50 µM of nonessential amino acids, 100 mM of BME, 5 mM of
thymidine, and 15 mM of the following nucleosides: adenosine, cytosine, guanosine, and uridine.
During this process, ESCs aggregate into multi-cellular embryoid bodies (EBs). After the first 2
days, the EBs were moved to a 15 mL of conical and allowed to settle for 5 min. The media was
aspirated and replaced with 10mL of fresh DFK5 containing 2 mM of RA and 600nM of SAG.
EBs were then cultured on the adhesive plates (Corning) for an additional 4 days for further
differentiation, and media was replaced every 2 days.

4.5.5 Fluorescence-activated cell sorting (FACS)
Before sorting, cells were washed with PBS and collected using trypsin. Cells were
pelleted by centrifugation, the trypsin was removed and the cells were washed with PBS. Cells
were resuspended in 1% w/v saline by repeated pipetting and passed through a 0.4-µm strainer to
ensure single-cell suspension. Cells were sorted on an iCyt Reflection HAPS2 cell sorter at the
Washington University Siteman Flow Cytometry Core. The gate was set relative to the cells
transfected with non-fluorescent control plasmids to eliminate background. Cells transfected
with a positive control fluorescent reporter plasmid were also used to eliminate false positive
singles. Flow cytometry metrics were analyzed using FlowJo Version 7.6.3 (TreeStar).

4.5.6 PCR amplification of inserts and sequencing
Genomic DNA was isolated from both RFP positive and negative populations of cells
using the QIAamp DNA Mini kit (Qiagen). The enhancer position sites were amplified from the
genomic DNA by primers that contains both Illumina sequencing adaptors and indexes,
permitting one-step amplification and sequencing library preparation. For each populations, two
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PCR reactions were performed with 100 ng gDNA and 23 cycles of amplification(10 µl Phusion
polymerase buffer, 1 µl 10 mM dNTP, 2.5 µl 10 µM forward and reverse primer, 1.5 µl DMSO,
0.5 µl (NEB) 50 ng DNA, 31 µl H2O; 16 cycles with 55 °C annealing temperature). The 2
reactions were then pooled and purified, and sequenced on Illumina MiSeq platform at the
Genome Technology Access Center (GTAC) at Washington University in St. Louis.

4.5.7 Bioinformatic data analysis
Paired-end sequences were aligned to the mouse reference genome (mm9) using bowtie2.
Read pairs were filtered from the final data set if either read failed to map to the genome, if both
reads did not map in the proper orientation, if the mapping quality score of both reads was less
than 25, or if neither read had a unique map location on the genome. Target sites were identified
as loci where paired reads both aligned entirely within a 1200-bp genomic region. To pinpoint
the active enhancer regions enriched for reads from positive libraries, the fold enrichment was
calculated as the normalized reads density from the RFP positive cells divided by that from RFP
positive negative cells.
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Chapter 5
Conclusion
For multicellular organisms to develop, stem cells must differentiate into a broad range of
specialized cells, all containing the same DNA. This remarkable feat is made possible by the
interaction of TFs and cis regulatory elements that control the spatial and temporal expression
patterns of specific sets of genes134. Although progress has been made toward understanding of
how transcription are regulated to generate distinct cell types, it could be greatly accelerated with
better molecular tools.
Chapter 2 describes a degradation domain based induction system for “Calling Cards”
method which maps the binding sites of TFs using piggybac transposons. This induction system
satisfies five important criteria: 1) The system has a low basal transposition activity when ‘off ’
and maintains high transposition activity when ‘on’; 2) The PBase fusion protein shows high
transposition activity almost equal to that of the unfused “wild type” PBase; 3) The system can
be applied across different cell lines with high performances; 4) The induction is reversible and
responds in a dose-dependent manner; 5) The chemical inducer does not interfere with general
cellular function. This induction system is successfully applied to PB transposon-mediated
“Calling Cards” method, which offers an alternative to chromatin immunoprecipitation (ChIP)
methods and furthermore the ability to record TF binding through cell division and at different
time periods of the development.
Chapter 3 describes the application of the “Calling Cards” method to study the role of
master regulatory Brd4-bound enhancers for sex differences in glioblastoma. Integration of Brd4
Calling Cards, H3K27ac ChIP-seq and RNA-seq data revealed a set of sex-specific regulatory
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genes and networks. Male-specific JQ1-sensitive targetable genes demonstrated functional
enrichment for glioblastoma, tumor angiogenesis, integrin signaling pathway, metabolic process
in addition to DNA-repair-deficiency disorders and cell proliferation. Female-specific JQ1sensitive targetable genes showed an enrichment in pathways involved semaphorin signaling,
chromosome aberrations, positive regulation of transcription, cell differentiation and tumor
progression. These results are indicative of sex-specific transcriptional programs regulated by
Brd4-bound enhancers. Identifying which specific pathways are critical to sex differences in
GBM will require further functional studies.
To record the activity of regulatory elements or enhancers, in Chapter 4, we developed a
high-throughput method for functional identification of active enhancers at different time periods
of development, named as Developmental Enhancer Sequencing (DevEn-seq). We demonstrated
that DevEn-seq is able to: 1) identify active enhancers more efficiently than regular reporter
methods; 2) trace enhancer activities along a cell lineage at a high temporal resolution without
being disturbed by the gene silencing effect caused by lentiviral sequences; 3) discover potential
makers that can be used to purify the progenitors of a given cell type. The knowledge obtained
through the application of this method would greatly expand our understanding of neural cell fate
specification and transcriptional network dynamics in development.
In summary, this dissertation contributes to the field of developmental biology by
providing useful methods for recording transcription factor binding and enhancer activity during
development. Because of the mounting evidence for transcriptional network’s contributions to
development and human disease, the identification of its two key elements TF and enhancers in
different cell types and under different biological conditions is currently of high priority in
biomedical research. The “Calling Cards” method and DevEn-seq will help to overcome the
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limitations currently to trace curbing the ability the activity of TFs and enhancers in many
disease-relevant cell types throughout development. These methods could allow for the more
comprehensive study of the roles of TFs and enhancers in human disease and ultimately guide
the reprogramming of embryonic or induced pluripotent stem cells to produce specific cell types
for personalized transplants, such as pancreatic beta cells to treat diabetes.
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Appendix One
Supplementary Figure for Chapter Two “An optimized, broadly applicable
piggyBac transposon induction system”

Figure 2.S1 Tunability of the FKBP-based PB transposon induction system measured by
GFP-split donors in HEK293 cell lines. (A) Schematic illustration of GFP-split donor mediated
transposition. The PB transposon disrupts the GFP gene. When the transposon is excised the
GFP coding sequence is reconstituted and the cells fluoresce. (B) The percentage of GFP
positive cells from the FKBP-PBase-FKBP fusion at different concentrations of Shld1.
Experiments were done in triplicates. (C) The mean fluorescence intensity from the FKBPPBase-FKBP fusion at different concentrations of Shld1. Experiments were done in triplicates.
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Supplementary Figure for Chapter Three “Brd4-bound enhancers drive
critical sex differences in glioblastoma”

Figure 3.S1 Quality assessment of transposon Calling Card, H3K27ac ChIP-seq and RNAseq experiments. Correlation heat map was made from replicates in male and female GBM
cells. Venn diagram depicts the shared H3K27ac-enriched peaks among replicates in male and
female GBM cells.
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Table 3.S1 Pathway analysis for sex-specific typical enhancers’ genes downregulated
following JQ1 treatment male and female GBM cells.
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Table 3.S2 Pathway enrichment analysis for differentially regulated genes in male and
female GBM cells
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